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Abstract
The contribution of mitochondria to cancer cell metabolism is a continuously
growing research field. Enhanced glycolysis and partial suppression of mitochondrial
metabolism, reciprocally dependent in many tumors, characterize the pro-survival and
proliferative Warburg phenotype. Voltage dependent anion channels (VDAC), in the
outer mitochondrial membrane (OMM), regulate the flux of most respiratory substrates
entering and exiting mitochondria. Thus, VDAC functions as a switch to turn-on (when
open), and off (when closed), mitochondrial metabolism. Previous work from our lab
showed that VDAC modulates mitochondrial metabolism in cancer cells, high cytosolic
free tubulin closes VDAC, and the synthetic VDAC-binding molecule erastin, antagonize
the inhibitory effect of tubulin on the channel.
Here, it is demonstrated that mitochondrial dysfunction leading to cell death after
the VDAC openers erastin/erastin-like compounds, or the chemotherapeutic agent
sorafenib, is induced by a ROS-dependent translocation of activated JNK to
mitochondria. Mitochondrial membrane potential (ΔΨm) was used as a global readout of
mitochondrial function and observed heterogeneity of ΔΨm, a phenomenon previously
described only qualitatively. Using an advanced confocal microscopy approach, ΔΨm
was quantified among cells in absolute values and proved that ΔΨm heterogeneity is an
intrinsic property of mitochondria. In addition, this quantitative approach to assess ΔΨm
by imaging, we developed a novel, sensitive and fast method to assess ΔΨm, NADH
generation and electron flow in permeabilized and intact cells using a combination of
plate reader and respirometry assays was developed. This method provides fast-tracked
medium throughput outcomes in phenotypic assays of mitochondria. Finally, VDAC was

xvii
used as a pharmacological target to identify in silico small molecules that bind to the
NADH-binding pocket of VDAC. NADH binding to the pocket closes the channel so
occupying this region with another molecule would prevent VDAC closure by
endogenous regulators, maintaining the channel in an open configuration. A lead
compound was identified that binds to VDAC, induce mitochondrial dysfunction, and
promote cell death.
Overall, the work described here contributes to a better understanding of cancer
metabolism, provides novel methods to study mitochondrial metabolism, and initiates a
potentially highly relevant translational application of VDAC modulation into cancer
treatment.

Chapter 1 : General Introduction to Cancer
Bioenergetics and VDAC
Cancer is a disease characterized by dysregulated cell division and uncontrolled
cell growth with the capacity to spread to different parts of the body [4]. The study of
cancer metabolism is among the oldest areas of research in cancer biology; preceding the
discovery of oncogenes and tumor suppressors by half a century. Cancer bioenergetics is
driven largely by the relative contribution of aerobic glycolysis and oxidative
phosphorylation (oxphos) to overall ATP generation. Cancer metabolism, however,
involves not just chemical reactions to cope with energy demands, but also those
necessary to maintain constant anabolism and catabolism [1, 2]. A reprogrammed
metabolism, considered a hallmark of cancer and observed across a plethora of tumor
cells, is a major driver of tumor metabolism [3-6]. The enhancement or suppression of
metabolic pathways in tumor cells that improve the cellular fitness required for rapid cell
division contribute to metabolic reprogramming [6, 7]. Despite its relevance to long-term
cell survival, reprogramming alone is not sufficient to explain metabolic adaptations to
the often rapid and high metabolic demands of a cancer cell. It is likely that rapid
metabolic changes be driven by fast acting mechanisms that modulate specific pathways
or proteins.
This dissertation sheds light on a specific contribution of mitochondrial
bioenergetics to cancer cell survival. Its main emphasis is on the development of a novel,
small molecules targeting Voltage Dependent Anion Channels (VDAC) in the outer
mitochondrial membrane (OMM) to regulate overall mitochondrial metabolism, upstream
of the electron transport chain and inhibit cancer cell proliferation.
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The Chemiosmotic hypothesis
It is almost impossible to talk about mitochondrial bioenergetics without
discussing the 1961, landmark discovery of the chemiosmotic hypothesis of Mitchell [8].
The relevance of mitochondria to cellular metabolism gained traction only in the early to
mid-20th century; when oxidation reactions in the mitochondrial matrix and ATP
synthesis were identified as main functions of this specialized organelle. However, it was
still unclear how energy from the electron transport chain (ETC) was transferred to
enzymes responsible for ATP synthesis. It is here that the chemiosmotic hypothesis of
Mitchell was a revelation for the mitochondria field [9]. Mitchell’s theory reconciled a
link between the proton electrochemical gradient formed across an impermeable, inner
mitochondrial membrane (IMM) and ATP synthesis. Up until then, biochemists were
preoccupied with finding an “energy-rich intermediate” that could supply the energy
required for the formation of ATP. Mitchell’s theory was not well received and found to
be highly controversial [10].
The chemiosmotic hypothesis postulated that the ETC and ATP synthase are
separated, but embedded in the same membrane. This membrane is impermeable to the
charge of protons but still allows their exchange across this barrier. Basically, Mitchell’s
theory stated that the flow of electrons, generated from the oxidation of nicotinamide
adenine dinucleotide (NADH) and the flavin group, through complexes of the ETC was
coupled to the outward translocation of protons across the IMM. Thus, creating a proton
motive force (pmf) used by the ATP synthase to synthesize ATP from adenosine
diphosphate (ADP) and inorganic phosphate (Pi) [8, 11]. His theory was controversial at
that time but was later confirmed by experimentation in mitochondria, chloroplasts and
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bacteria [9, 12-14]. Many years after his proposal, and multiple iterations of his theory,
Peter Mitchell was finally awarded the Nobel Prize in Chemistry in 1978.
Life as we know it might not have been possible without chemiosmosis. After all,
this is how the free energy of oxidation of food molecules is utilized to pump protons
across the IMM. Despite this remarkable feat, changing our understanding of membrane
transduction and transport, there was no consideration for the role of the OMM. This was
at least, in part, due to the leakiness of the OMM initially documented in 1957 by
Werkheiser and Bartley [15]. This led many researchers at the time to think of the OMM
as fully permeable layer, with no control over substrate flux nor bioenergetics of the
mitochondrion. Even after the establishment of the fluid mosaic model in 1972, showing
that proteins could fully integrate into lipid bilayers and were not fixed in their position, it
was still unclear whether the leaky OMM was an artifact of mitochondrial isolation or
founded in a more elegant, regulated transmembrane channel such as VDAC [16, 17].

Warburg Metabolism
By the early 20th century, German biochemist Otto Warburg, showed in tumor slices
and ascites cancer cells, that tumors produce more lactic acid than non-tumor cells even
at physiological partial pressures of oxygen [18, 19]. This particular phenotype, called
Warburg effect, is characterized by enhanced aerobic glycolysis. In tumor cells, relatively
low cytosolic ATP/ ADP ratios caused by a partial suppression of mitochondrial
metabolism prevents the normal inhibition of glycolysis mediated by high ATP. Warburg
even proposed that damaged mitochondria were the origin of cancer. According to his
hypothesis, only those cells with irreversible but incomplete damage to respiration were
capable of increasing the conversion of glucose to lactic acid (fermentation) in order to
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become cancerous [20]. The provocative hypothesis of failing mitochondria as the origin
of cancer was quickly challenged by Weinhouse and others, who demonstrated both high
glycolysis and oxidative metabolism in cancer tissues [21]. In fact, most tumors display a
certain

level

of enhanced

glycolysis

together with

functional

mitochondria.

Measurements of oxygen consumption, ΔΨm, NADH production, and ATP generation,
among other parameters, have confirmed that tumor mitochondria are metabolically
active [22-27]. Variations in the relative contribution of mitochondrial ATP to cellular
bioenergetics among different tumor types and even within the same tumor, suggest a
dynamic regulation of oxidative metabolism.
Further on, the biological effects induced by changes in the conformational states of
VDAC; how an increase in VDAC conductance reverses the Warburg phenotype and
promotes cell death; and, the relevance of VDAC as a pharmacological target to develop
novel cancer chemotherapies will be described [3].

Mitochondria, tumor metabolic flexibility and heterogeneity
The term metabolic inflexibility, coined in the late 90´s, refers to inadequate
responses of skeletal muscle to fuel changes in insulin-resistant obese patients [28, 29].
By contrast, metabolic flexibility alludes to the ability of muscle cells to switch from
fatty acid to glucose oxidation as a primary energy source. A “mitocentric” concept of
nutrient metabolism describes the storage, utilization and conversion of nutrients into
other metabolites, as a critical process to monitor energy homeostasis [30-32]. Research
to identify the molecular origins of metabolic flexibility has focused mostly on the
interplay between glucose and fatty acids, and/or the aberrant production of the fatty acid
precursor, malonyl-CoA.

Mitochondria, as an integral metabolic hub, are major
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contributors to metabolic flexibility. Similar to muscle cells, most cancer cells are
metabolically flexible. The different quantitative contributions of mitochondria to cellular
bioenergetics, together with genomic instability and differences in the microenvironment,
are important determinants of tumor heterogeneity [33-35]. Tumor metabolic
heterogeneity is increasingly recognized as a factor causing failures in cancer treatment
[36, 37]. Whether a tumor displays a predominantly glycolytic or oxidative metabolism
depends on gene expression as well as temporary and long-term epigenetic stimuli. In
addition, the dynamic relative contribution of glycolysis and oxphos is influenced by the
type of primary or metastatic tumor, intra-tumor regional differences, temporal variations
in the energetic demands and availability of glucose, fatty acids, ketone bodies, and
certain amino acids [38-40].
A reciprocal dependence of mitochondrial metabolism and enhanced glycolysis
has been shown in several cancer cell types under different experimental conditions,
including hypoxia and limitations in the availability of nutrients. The magnitude of
oxphos inhibition during hypoxia is influenced by the cell type and duration of the
hypoxic exposure. Prolonged hypoxia increases glycolysis in MCF-7 cells but not in
HeLa cells, although oxphos is the predominant source of ATP in both cell types [41].
Interestingly, in solid tumors, the respiratory chain is still fully functional at oxygen
levels as low as 0.5%, indicating that cancer cells exposed to < 2% oxygen in rapidly
growing and heterogeneously perfused tumors still produce ATP by oxphos [42, 43].
Under conditions that decrease pyruvate oxidation in the Krebs cycle,
mitochondria from tumor cells adapt to oxidize more glutamine as an energy source
sustaining tumor growth both through aerobic glycolysis and oxphos [44]. Nutrient
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availability not only influences tumor growth but also induces a switch from aerobic
glycolysis to oxphos in lymphoma and breast cancer cell lines cultured in glucose-free
media [45, 46]. If access to glucose and glutamine is limited, tumor cells adapt to utilize
instead, lactate, methionine, arginine, cysteine, asparagine, leucine, acetate, and even
lipids and proteins from the microenvironment to cope with the energy demands [47-53].
Overall, tumors display several metabolic alternatives to support continuous cell division
regardless of unfavorable environmental conditions.

Discovery and Structure of VDAC
The voltage dependent anion channel (VDAC) is now broadly accepted as the
channel in the OMM responsible for metabolite flux into and out of mitochondria. VDAC
is the most abundant protein in the OMM, and can cover up to

̴ 80% of membrane

surface area in high density regions [54]. The difficulty in distinguishing VDAC from the
solute carrier family (SLC25) foreshadowed the subtle differences that make VDAC a
unique, and rather elegant protein in its functions seated at the intersection of
mitochondrial metabolism and cytosolic signaling [55, 56]. The discovery of VDAC in
mitochondrial extracts from Paramecium aurelia, was by virtue of its characteristically
large, step-wise drops in conductance in planar lipid bilayers responding to a current of ̴
40 mV. In fact, this was by virtue of a serendipitous experiment by Marco Colombini and
Stan Schein to reconstitute calcium channels from the bacterium [57, 58]. It was only in
1979 that VDAC was first proposed as the reason for the “leaky” OMM first described by
Werkheiser and Bartley [15]. Furthermore, the identification of VDAC in mammalian
cells opened a new avenue in the research and understanding of mitochondrial
metabolism [57, 59]. VDAC, which is comprised of three isoforms sharing between 65-

7
70% nucleotide sequence homology, is a polypeptide of ~30 kDa (VDAC 1 and 3: 280
amino acids; VDAC 2: 291 amino acids). In most mammalian somatic cells, including
cancer cells, VDAC 1 and 2 are the most abundant isoforms, whereas VDAC 3 is the
least expressed. However, VDAC 3 is the dominant isoform in testis and spermatozoa
[60, 61].
VDAC structure is defined by beta barrels enclosinh an aqueous channel of 2.5-3
nm internal diameter in the open state, that allows the passage of molecules up to ~5 kDa
[29-31]. The current consensus about VDAC structure shows differences with the
originally proposed model by Colombini that was based on biochemical and functional
data [30, 32]. Structural studies using NMR and X-ray crystallography show VDAC 1
and 2 as transmembrane, β-barrel proteins with 19 antiparallel, β-strands, with the
exception of strands 1 and 19. Both isoforms also have an N-terminal, α-helical region
located within the pore [33, 34]. VDAC 3 has yet to be crystallized, but has a high degree
of sequence similarity.

Crucial role of VDAC in mitochondrial bioenergetics
VDAC1, VDAC2 and VDAC3 are at the interphase between the mitochondria
OMM and the cytosol. The important location of VDAC allows the protein to control
metabolite flux and ATP entering and leaving mitochondria. At present, it is unclear if
the flux of metabolites and nucleotides through VDAC is different among tumor cell
types, and if it is isoform specific.
To access the mitochondrial matrix, most anionic substrates that cross the OMM
through VDAC, are further transported through the IMM by several finely tuned, specific
carriers[62]. Pyruvate, fatty acids, and the amino acids; glutamine, glycine, serine,
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leucine, isoleucine, valine, and tryptophan, generate acetyl-coenzyme A (AcCoA), that
fuels the Krebs (tricarboxylic acid cycle). A cycle of oxidation generates 1,4dihydronicotinamide

adenine

dinucleotide

(NADH),

and

dihydroflavine-adenine

nucleotide (FADH2), the primary electron donors to the ETC [63]. Electrons flowing
through the respiratory chain, formed by complexes I-IV, reducing the final acceptor molecular oxygen to water. Single electron leaks from complexes I, II, and III happen
simultaneously, to form the superoxide anion (O2•-), that is further rapidly converted into
other

reactive

oxygen

species

(ROS)

[64,

65].

The metabolic fitness of mitochondria in any cell type also depends on the
generation of the negatively charged matrix ΔΨm, by protons accumulating in the
intermembrane space (IMS) of the mitochondrion during oxphos [66, 67]. Newly
synthesized ATP is transported to the IMS through the adenine nucleotide translocator
(ANT), located in the IMM, and exchanged for ADP in a 1:1 molar ratio to be finally
released to the cytosol through VDAC [68, 69]. AMP, an adenine nucleotide directly
involved in the allosteric activation of phosphofructokinase and the persistence of
glycolysis, also cross the OMM through VDAC. Therefore, regulation of VDAC opening
influences the ATP/AMP ratio, which in turn, modulates the activation of AMP-activated
protein

kinase

(AMPK)

and

the

rate

of

glycolysis

[70,

71].

In some human cell models, hypoxia induced the synthesis of a C-terminal truncated
form of VDAC 1, with similar channel activity and voltage dependency as the full-length
channel. Truncated VDAC 1 was linked to an upregulation of oxphos and glycolysis, as
well as resistance to apoptosis [72-75]. Thus, the magnitude of metabolite fluxes to
support Oxphos and ATP synthesis ultimately depends on VDAC conductance (Fig. 1-1).

9

Figure 1-1. Main features of mitochondrial metabolism.
Metabolites and respiratory substrates including pyruvate, ADP, and inorganic phosphate
(Pi), cross the outer mitochondrial membrane through voltage dependent anion channels
(VDAC). Catabolism of respiratory substrates in the Krebs cycle generates NADH and
FADH2, which fuel the electron transport chain (ETC; complexes I–IV) to support
oxidative phosphorylation. The Krebs cycle also produces metabolic intermediaries that are
released to the cytosol for the biosynthesis of proteins and lipids. Protons pumped by
complex 1, III, and IV generates ΔΨm. Protons move back across the IMM mainly by
driving the synthesis of ATP from ADP and Pi, by interacting with the F1F0 ATP synthase
(complex V). Mitochondrial ATP is exported from the matrix by the adenine nucleotide
transporter (ANT) and released to the cytosol through VDAC. Flow of electrons through
complexes I, II, and III also generates reactive oxygen species (ROS). AcCoA, acetyl CoA;
α-KG, alpha ketoglutarate; IMM, inner mitochondrial membrane; OMM, outer
mitochondrial membrane; and ROS, reactive oxygen species. Modified from [3] with
permission.
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VDAC isoform specific roles
Each isoform was found to be dispensable in its relevance to cell survival. VDAC
1 knockout (KO) mice have low fertility, indicative of partial embryonic lethality. VDAC
3 KO, male mice maintain their copulatory activity, but were found to be infertile.
However, VDAC 3 KO, female mice have normal fertility. VDAC 1 and 2 double KO
mice are also infertile, and have severe growth retardation [25, 26]. VDAC 1 is also
implicated in the release of cytochrome c in the apoptotic cascade. However, VDAC 1
deficient animal models do not show a difference in apoptosis. Additionally, it is
generally accepted that the function of each VDAC isoform may vary depending on the
tissue type being considered [76]. An example is seen in cardiac and skeletal muscle
fibers lacking VDAC 1; with there being is a reduction in ADP-stimulated respiration. A
similar reduction in oxygen consumption was recorded in VDAC 3 deficient cardiac
muscle fibers but not skeletal muscle types [27, 28].

VDAC electrophysiology and gating characteristics
The characteristics displayed by VDAC reconstituted in planar lipid bilayers
(PLB); showing a voltage-dependent conductance and anion selectivity is how Colombini
and Shein decided on the naming the channel [56]. When inserted in non-polarized or
weakly polarized cholesterol based PLB, at voltages ± 20mV, VDAC stays mostly in the
high conductance, anion selective (2:1 for equally mobile Cl-/K+) open-state. The average
VDAC channel conductance in the open-state, is 4 nS in 1 M KCl, maintaining a
permeability available to large anions such as ADP3-, HPO42-, phosphocreatine2- [77]. By
contrast, voltage potentials greater than ± 40 mV reduces conductance by about half,
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along with potential conformational changes that reduce pore size to roughly 1.8 nM,
engaging the so called closed- state of VDAC [78, 79]. The channel remains permeable to
small ions, with an increased permeability for small cations including Na+, K+, and Ca2+
[80-82]. ATP is no longer permeant in the closed state of VDAC. VDAC is a channel
selective for anionic metabolites and small cations as shown initially by Colombini, and
later confirmed by other groups [70, 83, 84].
Although it is currently not possible to determine membrane potentials across the
OMM in live cells, plausible theoretical approaches suggest the existence of polarization
of the OMM in intact cells [85]. Moreover, the ~ 0.6 pH difference reported between the
cytosol and the IMS [86] corresponds to a -15 - 20 mV potential. It is appropriate to keep
in mind here that VDAC in the intracellular environment and interacts with a multitude of
proteins involved in glycolysis and oxphos; operating as a central hub for protein
interactions, particularly those that sequester ATP that is leaving the mitochondria. In this
native cellular environment, it is likely that the voltages required to close VDAC is much
lower. Indeed, there is evidence for this in the interactions with tubulin and VDAC as we
and others have shown [70, 87, 88]. Since this value of membrane potential falls in the
range in which reconstituted VDAC display a mild decrease in conductance [89], it is
theoretically possible that voltage actually contributes to the regulation of VDAC
opening. Generally, regulation of VDAC inducing a shift from the open state to the
closed state, reduces and increases the flux of negatively charged metabolic substrates
and cations, respectively (Fig. 1-2). Although gating and selectivity for VDAC 1 and
VDAC 2 are very similar in different cell types, the detailed molecular determinants of
voltage gating are still incompletely understood [90, 91].
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Figure 1-2. VDAC regulation of cancer bioenergetics in metabolically flexible tumors.
A.) VDAC opening in cancer cells promotes oxidative metabolism and reverses the
Warburg phenotype. B.) The contribution of glycolysis to cancer cell bioenergetics is
influenced by the type of tumor, and regional differences, among other variables. A
dynamic reversal of the Warburg phenotype influences cell proliferation. From [3] with
permission.
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Endogenous regulation of VDAC gating
Even though VDAC was initially considered constitutively open, like a molecular
sieve, subsequent research both in vitro and in intact cells, showed regulation of VDAC
conductance by several endogenous molecules. VDAC conductance is modulated by α/β
tubulin heterodimers [87, 92, 93]; hexokinase [94, 95]; bcl2 family members [96];
glutamate

[97]

;and

NADH

[98].

Post-translational

modifications,

mainly

phosphorylation by protein kinases, GSK3β, protein kinase A (PKA) and protein kinase
C epsilon (PKCε), blocks or inhibits association of VDAC with other proteins, such as
Bax and tBid, and regulates VDAC opening [99-101]. Moreover, PKA-dependent VDAC
phosphorylation and GSK3β-mediated VDAC2 phosphorylation increase VDAC
conductance and also the sensitivity to tubulin inhibition [100, 102, 103]. VDAC opening
is also modulated by protein-protein interactions with actin, p53, mitochondrial creatine
kinase, and alpha-synuclein, among others [104, 105].

VDAC as a metabolic switch
Overall, VDAC operates as a metabolic switch that, in the on-phase (open state),
maximizes the flux of metabolites for optimal mitochondrial function, whereas during the
off-phase (closed state), suppresses mitochondrial metabolism. Thus, regulation of this
channel has an amplifying effect on several intra and extra-mitochondrial pathways
modulating cancer metabolism and bioenergetics. The dynamic changes in ATP and
biosynthetic demands, ranging from seconds to minutes or even hours, days and weeks,
imply the coexistence of both metabolic reprogramming and fast acting regulatory
mechanisms. VDAC is, very likely, one of the rapidly adapting mechanisms that is
responsive to interactions with other OMM and cytosolic proteins and soluble factors,
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along with transient or permanent posttranslational modifications. At present, it is
unknown if metabolic reprogramming, that affects several mitochondria-related
pathways, modulates VDAC conductance.
Beyond the role in mitochondrial metabolism, VDAC is also a prognostic biomarker
for certain types of human cancer [106, 107]. High expression of VDAC1 has been
associated with unfavorable outcomes in cancers from lung, head and neck, breast and
liver [106, 108, 109]. High transcript levels of VDAC2 in multiple tumors, including
melanoma, epithelial thyroid tumors, and breast cancer have been reported in the cancer
databases cBioportal (http://www.cbioportal.org), and the Human Protein Atlas
(hhtp://www.proteinatlas.org).

In head and neck cancer and in liver cancer, high

expression of VDAC 2 is also associated with a poor outcome. Interestingly, VDAC3
expression seems not to be of prognostic value for human cancer suggesting isoform
specific effects on cell proliferation.

VDAC’s influence on the cytosolic ATP/ADP ratio
In general, approximately 95% of ATP in quiescent cells is produced by oxphos, with
the remaining 5% generated through the pay-off phase of glycolysis in the cytosol, and
the succinyl-CoA ligase reaction of the Krebs cycle. Full mitochondrial oxidation of one
molecule of glucose generates ~32 moles of ATP, as estimated by different methods,
compared to the 2 moles of ATP/ mole of glucose during glycolysis [110]. Although the
total amount of mitochondrial ATP calculated considers the currently accepted proton
stoichiometry for ATP synthesis, ATP/ ADP-Pi exchange, respiration, and the
malate/aspartate shuttle, the actual ATP yield could be less due to proton leak into the
mitochondrial matrix [110-113]. The relatively low ATP demand for cell division
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compared to the energy requirements for maintenance of cellular functions, mainly the
activity of the Na+-K+ ATPase, suggests that ATP generation is not a limiting factor to
sustain rapid cell proliferation [114-117]. High ATP-ADP in the cytosol inhibits
phosphofructokinase-1 (PFK-1), a rate limiting step in the glycolytic pathway, among
other possible mechanisms blocking glycolysis [115, 118].

The ATP-dependent

inhibitory mechanisms, together with regulation of other pathways, may be key to explain
the reciprocal dependence between mitochondrial metabolism and glycolysis in several
tumor types. By contrast, a partial suppression of mitochondrial metabolism in cancer
cells contributes to a low cytosolic ATP/ADP ratio; releasing the brake on glycolysis and
favoring the Warburg phenotype [3]. Tumor cells also display “glucose avidity,” an
increased uptake of glucose compared to non-proliferating cells. Compared to nonproliferating cells, cancer cells can generate up to 90% of total ATP by glycolysis [26,
119].

VDAC control over metabolic intermediaries
The conformational open or closed state of VDAC, by regulating the flux of
respiratory substrates, is a major determinant of cytosolic ATP/ADP ratios to favor or
oppose the pro-proliferative Warburg phenotype. The predominance of open or closed
conformational states of VDAC, not only determines the bioenergetic efficiency of
mitochondria, but also the ability to contribute metabolic intermediaries to the synthesis
of amino acids, fatty acids, nucleotides, cholesterol, glucose and heme [120]. Rapidly
dividing cells face a constant challenge to produce new macromolecules to approximately
double the biomass before mitosis. In the Warburg metabolism, the major sources of
carbon backbones are glucose, glutamine and fatty acids. Similar to glycolytic
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intermediates, Krebs cycle intermediates are also used as precursors for biosynthesis of
macromolecules. A continuous supply of precursors, sustained by anaplerotic pathways,
“refills” the cycle with intermediates to replace those that have been already used for
biosynthesis. Glutaminolysis, which produces α-ketoglutarate from glutamine, and
pyruvate carboxylation, which produces oxaloacetate from glucose/ pyruvate are major
contributors to anaplerotic fluxes in cancer cells [121-123]. Oxidation of the branchedchain amino acids (BCAAs) isoleucine and valine also provides an anaplerotic flux in
some tumors. If glucose supply is sufficient for energy generation, glutamine-derived αketoglutarate and oxaloacetate are utilized for the synthesis of nonessential amino acids,
whereas citrate exported to the cytosol, is converted into AcCoA and utilized for the
synthesis of fatty acids, cholesterol, and amino acids. Glutamine is also a nitrogen donor
in purine and pyrimidine synthesis, and a precursor for the synthesis of the antioxidant
glutathione [124-127]. Recently, one-carbon metabolism, a set of reactions that transfer
one-carbon units (methyl groups) from serine and glycine, has been shown to be
important for de novo synthesis of purines and thymidylate synthase in highly
proliferative tumors [128].

Mitochondrial targets for chemotherapy
Drugs used in conventional chemotherapy promote cell death or inhibit cell growth by
blocking DNA synthesis and replication, stabilizing or destabilizing microtubules, or by
targeting specific enzymes or receptors. By contrast, the relatively new “metabolic”
approaches for cancer treatment were mostly focused on glycolysis inhibition. Only more
recently, mitochondrial metabolism has emerged as a target to arrest tumor growth [129131]. Epidemiologic evidence showed that patients taking metformin, a first line
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treatment for type II diabetes and inhibitor of complex I of the ETC, had decreased
prevalence of certain types of cancer. These findings contributed to the interest of
targeting mitochondria from a chemotherapeutic perspective. Beyond metformin,
inhibition of mitochondrial metabolism as a mechanism to suppress aberrant cell
proliferation has been in consideration for more than a decade [132, 133].
Here, some of the main pharmacological approaches proposed to inhibit glycolysis
and to modulate mitochondrial metabolism will be briefly described (Fig.1- 3).
Glycolysis inhibitors
Pharmacological approaches to inhibit glycolysis comprise of blockage of glucose
uptake and inhibition of specific regulatory steps in the glycolytic pathway.
Inhibitors of the glucose transporter family.
Cancer cells express higher levels of glucose transporters, in particular GLUT1,
compared to normal cells [134]. The polyphenolic compound, WZB117 inhibits GLUT1
and downregulates the expression of the glycolytic enzymes hexokinase II (HK-II) and
pyruvate kinase M2 (PKM2), leading to decreased cellular ATP, ER-stress and cell cycle
arrest in non-small cell lung cancer cells both in vitro and in vivo [135, 136]. The natural
polyphenol, phloretin, similar to WZB117, inhibits GLUT2 mRNA and protein
expression by blocking hepatocyte nuclear factor 6 (HNF6). Phloretin alone or in
combination with conventional chemotherapy, suppressed growth of xenograft tumors in
nude mice [137, 138]. A major downside of these compounds was the lack of selectivity
since GLUT transporters are ubiquitously distributed in mammalian cells, increasing the
risk of adverse effects and systemic toxicity [139].
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Hexokinase inhibitors.
Hexokinase -II (HK-II) is a rate-limiting enzyme in the glycolytic pathway. HK-II
also influences the pentose phosphate pathway, and contributes to an accelerated glucose
metabolism in cancer. Several HK-II inhibitors have been developed after the discovery
of the glucose analogue 2-deoxy-d-glucose (2-DG). In tumor cells, a high uptake of 2DG, favored by the high expression of GLUT transporters, leads to increased conversion
of 2-DG to 2-DG-6-phosphate (2-DG-P) by HK-II. 2-DG-P competes with G-6-P for the
next step as a substrate for phosphoglucose isomerase in the glycolytic pathway [140]. In
contrast to G-6-P, 2-DG-P cannot be metabolized by phosphoglucose isomerase and
therefore accumulates in the cytosol; haulting glycolysis. When combined with cisplatin,
2-DG decreases ATP production, and promotes ROS production in various cancers [141].
In clinical trials, 2-DG had adverse effects including: fatigue, gastric bleeding and
hyperglycemia. Additionally, 2-DG failed to slow tumor growth in more than half of the
population studied [142, 143]. Clinical trials of hexokinase inhibitors lonidamine –an
indazole-3-carboxylic acid derivative, GEN-27-an isoflavanoid, benserazide – a
peripherally acting aromatic L-amino acid decarboxylase, and resveratrol –a polyphenol,
all yielded inconclusive results as anti-proliferative agents [144, 145].
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Figure 1-3. Mitochondrial and glycolytic inhibitors.
Inhibitors of glycolysis or modulators of mitochondrial metabolism target specific
pathways that alter the cytosolic and mitochondrial utilization of pyruvate, glutamine and
fatty acids. ACC: acetyl-Coa carboxylase; DCA: dichloroacetate; FASN: fatty acid
synthase; GLUT 1 and GLUT 2: glucose transporters; 2-DG: 2-deoxy-d-Glucose; GLS1:
glutaminase; GS: glutamine synthetase; IMM: inner mitochondrial membrane; IMS:
intermembrane space; OMM: outer mitochondrial membrane; PC: pyruvate carboxylase;
PD: pyruvate dehydrogenase; PDK: pyruvate dehydrogenase kinase. Modified from [2].

20

Modulators of mitochondrial metabolism
Generally, mitochondrial inhibitors exert an anti-proliferative effect, likely by
primarily decreasing the biosynthetic capabilities of mitochondria. By contrast, enhancers
of mitochondrial metabolism increase ROS; leading to oxidative stress and mitochondrial
dysfunction. Additionally, increased mitochondrial metabolism in metabolically flexible
tumors indirectly decreases glycolysis; therefore reverting Warburg metabolism.
Glutamine metabolism inhibitors.
Tumor cells utilize glutamine more than any other amino acid [146, 147].
Therefore, the so-called cancer “glutamine addiction” is a potential metabolic
vulnerability. Glutamine replenishes the citric acid cycle with the intermediates αketoglutarate, oxaloacetate, and pyruvate during anaplerosis in proliferating cells [147,
148]. Specific inhibitors of glutaminase, that converts glutamine to glutamate and is
upregulated in most cancers, have shown modest success in preclinical animal models
[149]. Bis-2-(5-phenylacetamido-1, 3, 4-thiadiazol-2-yl)ethyl sulfide (BPTES), the best
characterized glutaminase inhibitor, slowed the progression of hepatocarcinoma, renal
carcinoma, lymphoma, and prostate cancers [150]. CB-839, a more potent and orally
bioavailable derivative of BPTES, currently in clinical trials as a monotherapy or
combined to conventional chemotherapy, also inhibits glutaminase [151, 152]. Another
glutamine-related chemotherapeutic target is glutamine synthetase, which is highly
expressed in breast, lung and ovarian cancers [153]. Glutamine synthetase catalyzes de
novo synthesis of glutamine and is inhibited by the competitive inhibitor, methionine
sulfoximine, and has shown anticancer activity in gastric cancer and sarcoma cells [154].
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Fatty acids metabolism inhibitors.
Dysregulation of fatty acid (FA) synthesis and oxidation is another distinctive
feature of cancer metabolism [155]. Upregulation of fatty acid synthase (FAS) and acetyl
CoA carboxylase (ACC), among other enzymes of the FA biosynthetic pathway, sustain
rapid cell proliferation. Increased FA synthesis favors membrane biogenesis, growth and
survival even during nutrient starvation. Thus, inhibition of FA synthesis is being
explored as a strategy to slow tumor growth. TOFA (5-(tetradecyloxy)-2-furoic acid),
soraphen A, ND-646, and ND-654 are well characterized AAC inhibitors [156]. TVB2640, that targets FAS, currently in clinical trials, is used in combination with paclitaxel
in patients with non-small cell lung, ovarian, and breast cancer with specific KRAS
mutations [157]. An alternative approach to pharmacological inhibition of FAS, is to
mimicking a low energy state in tumor cells to activate the AMP-activated protein kinase
(AMPK) that directly inhibits ACC, resulting in an inhibition of FAS [158].
Exogenous and endogenous FA are oxidized in mitochondria and peroxisomes.
FA are converted to fatty acyl-CoAs, and later to fatty acyl-carnitine by the carnitine
palmitoyltransferase 1 (CPT1), a mitochondrial rate-limiting enzyme for FA oxidation.
Fatty acyl-carnitines, shuttled to the IMM, are further translocated to the mitochondrial
matrix for entering successive cycles of β-oxidation. Although evidence of mutations of
FA oxidation enzymes in cancer are scarce, overexpression of CPT1 enzymes have been
observed in chronic lymphocytic leukemia cells and breast cancer; raising questions
about the feasibility of CPT1 as a pharmacological target [159]. However, etomoxir, a
common CPT1 pan inhibitor, that showed anticancer activity in high doses against
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leukemia, breast and prostate cancer cells was removed from clinical trials because of
complications related to diabetes and heart failure [160] [161].
Pyruvate Dehydrogenase Complex modulators.
Pyruvate, a product of the breakdown of glucose, is in equilibrium with alanine
and lactate in the cytosol [162-164]. After entering mitochondria, pyruvate is either
reversibly converted to AcCoA by the pyruvate dehydrogenase complex (PDC) or
irreversibly carboxylated to form oxaloacetate by pyruvate carboxylase. In many cancers,
constitutively inhibited PDC is proposed as a driver for tumor metabolic flexibility and
the Warburg effect [164]. PDC is regulated mainly by reversible phosphorylation of
serines by pyruvate dehydrogenase kinases (PDK1-4) that contain a small binding site for
pyruvate. Phosphorylation inhibits PDC and favors glycolysis. Thus, pyruvate is an
endogenous natural PDK inhibitor and a PDC substrate. The balance of the activities of
both PDC and PDK, subjected to multiple levels of regulation, determines if pyruvate
undergoes full oxidation in the Krebs cycle or is converted to lactate in the cytosol.
The pyruvate analog dichloroacetate (DCA), used to treat lactic acidosis, inhibits
PDK, releasing the inhibition on PDC and promoting the conversion of pyruvate to
AcCoA[165]. Thus, DCA shifts away glucose metabolism from glycolysis towards the
Krebs cycle. DCA is a readily available orphan drug, not approved for cancer therapy.
Numerous preclinical studies have used DCA in combination with anticancer agents.
Phase one trials in patients with glioblastoma and other recurrent brain tumors showed
that oral DCA was well tolerated in patients using the dose range established for
metabolic diseases. Dose-dependent peripheral neuropathies observed in trials were
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controlled by reducing the required dose of DCA [166]. Mitaplatin, containing two
molecules of DCA bound to cisplatin, was developed as an alternative to DCA [167].
Once inside the cell, mitaplatin releases cisplatin to target nuclear DNA while DCA
inhibits PDK reversing the Warburg effect. Diammineplatinum (II) complexes are a new
generation of DCA analogs targeting different binding sites on PDKs [168].
VDAC as a pharmacological target
One of the goals of this thesis work is to shed light on VDAC as a druggable
protein; expanding the pharmacological tools specifically designed to target regulation of
channel conductance. Conventional chemotherapeutic agents promote cell death or arrest
cell proliferation by blocking DNA synthesis and replication, inhibiting specific enzymes
or receptors, or by destabilizing or stabilizing microtubules. By contrast, “metabolic”
approaches for cancer treatment have mostly focused on the inhibition of glycolysis.
Only more recently, mitochondria and mitochondrial metabolism emerged as a source of
targets to prevent or slow tumor progression [129-131, 169-171]. In general, a restriction
of mitochondrial oxidation of substrates decreases the amount of each intermediary
released to the cytosol for the biosynthesis of macromolecules. By contrast, enhancement
of mitochondrial metabolism leads to increased oxidation of substrates and ATP
generation, increased ROS formation with subsequent oxidative stress, and reversal of the
Warburg phenotype. These two ways of modulating mitochondrial metabolism decrease
cell proliferation and promote cell death.
A remarkable and unique feature of VDAC is the ability to globally control
mitochondrial metabolism by simply increasing or decreasing the conductance. In a broad
sense, VDAC is a “first-step” in mitochondrial metabolism. Although mitochondrial
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bioenergetics is regulated at multiple levels, VDAC opening in cancer cells leads to three
major biological effects: maximization of full oxidation because of augmented entry of
substrates into mitochondria; subsequent decrease in glycolysis due to a high cytosolic
ATP/ADP ratio promoted by maximum generation of mitochondrial ATP; and increased
formation of ROS following the enhanced activity of the ETC. Particularly relevant for
cancer metabolism, VDAC has been shown to also serve as a docking site for a group of
cytosolic proteins including hexokinase-II and the Bcl-2 family of proteins. While
VDAC1 is considered a pro-apoptotic protein and VDAC 2 seems to be anti-apoptotic,
some controversy still remains about the role of VDAC for apoptotic cell death [172174]. Regardless, because of the obvious relevance of apoptosis for tumor growth,
VDAC 1 has emerged as a candidate to develop VDAC 1-targeting molecules. Several
peptides (mastoparan, mitoparan, and TEAM-VP); an oligonucleotide (G3139);
molecules of unrelated structures (dicyclohexylcarbodiimide, estradiol, among several
others); and more recently an miRNA (miR-7), have been reported to target VDAC and
be pro or anti-apoptotic. These different molecules either regulate VDAC 1 activity,
expression, oligomerization, interaction with HK-II or posttranslational modifications.
An excellent review providing a brief description of compounds interacting mostly with
VDAC 1, have been published by De Pinto group [175].
Regardless of recent developments including a resolved NMR structure of VDAC
1 with NADH bound [176], and the identification of a cholesterol binding site [177], drug
discovery of VDAC modulators still faces major challenges. Despite the growing number
of compounds that have an effect on VDAC, potential isoform specificities and
identification of ligand binding sites for each of the reported molecules, are still
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unknown. An analysis of the structures of anti-cancer drugs acting on VDAC, shows a
lack of common structural motifs. In addition, a well-defined druggable binding site has
not been reported before our studies. Even the gold standard for assessing VDAC gating,
electrophysiology of the channel reconstituted in PLB, is not definitive. A different lipid
composition of the artificial membranes compared to the OMM, lack of cytosolic soluble
factors and protein interactions, limited knowledge about the effect of post-translational
modifications, potential artifacts introduced during the isolation and insertion of VDAC,
as well as isoform specific responses, may lead to inconclusive and confounding results.
Moreover, a compound of interest could eventually affect VDAC gating inserted into
bilayers not only by interacting directly or indirectly with the channel, but also by
altering the lipid bilayer surrounding the channel [178].
During the last five years, we showed that VDAC regulates mitochondrial
metabolism in live cancer cells using a combination of knockdown strategies and
confocal microscopy of ΔΨm and NADH, among other techniques. Previous work from
the lab also provided evidence that increased cytosolic free tubulin dynamically
correlates with changes in ΔΨm, suggesting a direct effect of free tubulin on VDAC
opening [87]. Those initial findings about the effect of VDAC regulation by free tubulin
on mitochondrial metabolism in intact cells, were published shortly after dimeric α/β
tubulin was shown to block VDAC conductance in lipid bilayers and in isolated
mitochondria [92]. Also, VDAC 1 and 2 isolated from VDAC double-knockdown HepG2
cells in all combinations, inserted into lipid bilayers, were equally sensitive to tubulin
inhibition. By contrast, VDAC 3 was insensitive at tubulin concentrations even five-fold
higher than those used to inhibit VDAC1 and 2 [87]. In parallel with those experiments,
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blockage of the inhibitory effect of tubulin on VDAC by erastin, increased mitochondrial
metabolism [87]. Erastin is a VDAC 1 and 2-binding molecule identified in a synthetic
lethal chemical screening shown to induce non-apoptotic cell death [179]. Interestingly,
cell death induced by erastin was blocked by antioxidants but not prevented by pancaspase inhibitors, suggesting that erastin-induced cell death was ROS-dependent [180].
The effect of erastin on mitochondrial metabolism was independent of the inhibition of
the cysteine/glutamine antiporter system xc−, another known target of erastin
(unpublished).

Later on, using a cell-based high throughput screen, some of the

foundational work preceding this project, identified a series of erastin-like compounds
that enhance mitochondrial metabolism, promote oxidative stress leading to
mitochondrial dysfunction, and decrease glycolysis as measured by lactate release (antiWarburg) [181-183]. The earliest work contributing to my thesis is where we show that
mitochondrial dysfunction promoted by erastin/ erastin-like molecules was mediated by a
ROS-dependent translocation of activated JNK to mitochondria [184]. The VDAC–
tubulin interaction represents a new pharmacological target to turn a pro-proliferative
phenotype into a cytotoxic, mitochondrial-dependent pro-oxidant metabolism. Based on
our studies on VDAC regulation in cancer, we have proposed that VDAC opening is a
pro-oxidant anti-Warburg switch that promote cancer cell death [171, 184, 185].
Overall, pharmacologically-induced VDAC opening, as achieved by reversal of
the inhibitory effect of tubulin on VDAC, triggers two distinct and nearly simultaneous
effects: the increase of mitochondrial metabolism and oxphos with subsequent decrease
of glycolysis (anti-Warburg), and the increase in ROS formation, causing oxidative
stress. Because of the metabolic heterogeneity of tumors, it is possible that the adverse
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effects of ROS accumulation and glycolysis inhibition on cell survival and proliferation
be different among cells. A VDAC-dependent increase in ROS production would likely
be detrimental for highly glycolytic cells, not typically exposed to high levels of
mitochondrial ROS. The combination of reversal of Warburg metabolism and oxidative
stress by erastin-like compounds caused cell death to human hepatocarcinoma cell lines
in culture and slowed tumor growth in a xenograft model of Huh7 cells [181, 182].

Aims
The data in the subsequent chapters was gathered with the intention of adding to
the pool of knowledge relating to a relatively new field; VDAC regulation of
mitochondrial bioenergetics in the context of the cancer cell. This work explores: 1.)
consequences of VDAC opening; reverting the Warburg Effect in Cancer cells. 2.)
Intercellular - ΔΨm heterogeneity, high content drug screening with a focus on key
mitochondrial bioenergetics parameters (ΔΨm, NADH, oxygen consumption). 3.)
VDAC druggability and gating influences on cancer cell fate. In this effort, the follow
specific aims have been addressed:
Aim 1: Determine the effect of erastin-like compounds on mitochondrial metabolism
and cell survival.
Aim 2: Determine biological effects of candidate compounds.
Sub-Aim 2.1: Assess intercellular differences in mitochondrial membrane
potential in relative and absolute values.
Sub-Aim 2.2: Develop a medium throughput method for small molecule drug
screening in intact and permeabilized cells.
Aim 3: Screen the South Carolina Compound Collection (SC3) to identify small
molecules that bind to VDAC (NADH pocket).
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Chapter 2 : Materials and Methods
General Methods
Materials/ reagents
Antimycin A, rotenone, carbonyl cyanide 3-chlorophenylhydrazone (CCCP),
oligomycin, zosuquidar, tetramethylrhodamine methyl ester (TMRM) and bis (1,3dibutylbarbituric acid) trimethine oxonol (DiBAC4(3)) were purchased from Millipore
Sigma (Burlington, MA). FLIPR Membrane Potential Assay Kit (FLIPR) from Molecular
Devices (Sunnyvale, CA). Fetal bovine serum (FBS) from Atlanta Biologicals. Penicillin,
streptomycin, 100X MEM Nonessential amino acids, RPMI 1640 containing 2.05 Mm Lglutamine, FxCycle™ PI/RNAse Staining Solution, paraformaldehyde and Rhodamine
123 were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Eagle’s
Minimum Essential Medium was purchased from the American Type Culture Collection
(ATCC; Manassas, VA, ). Annexin V, Alexa Fluor 488 conjugate, Hoechst 33342, and
MitoSOX Red were purchased from Thermo Fisher Scientific (Waltham, MA);
SP600125, JNK inhibitor VIII, N-acetyl-cysteine (NAC), propidium iodide (PI), S3QEL
2 and Necrostatin-1 from Millipore Sigma (Burlington, MA); X1 (5-chloro-N[4-chloro-3(trifluoromethyl)pheyl]-2-(ethylsulfonyl)-4-pyrimidinecarboxamide) from Chembridge
Corporation (San Diego, CA); Tat-Sab peptide from NeoBiolab (Cambridge, MA) and
SOR from Cayman Chemical (Ann Arbor, MI). Antibodies against p-JNK (Cat. # 9251)
and SAPK/JNK antibodies were purchased from Cell Signaling Technology (Beverly,
MA); β-actin (Cat. # sc-47778) and Tom20 (Cat. # sc-17764) from Santa Cruz
Biotechnology; horseradish peroxidase–conjugated secondary antibodies (Cat. # ab6721)
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from Abcam and Pierce Goat Anti-Mouse Poly-HRP (Cat. # QF218146) from Thermo
Fisher Scientific). All other chemicals were analytical grade.
Cell culture
HepG2

(Cat#

HB-8065),

and

SNU-449

(Cat

#

CRL-2234),

human

hepatocarcinoma cells, and BJ1 fibroblasts, and HCC4006 human lung adenocarcinoma
(CR1-2871) cells were purchased from the American Tissue Culture Collection (ATCC)
(Manassas, VA). Huh7 human hepatocarcinoma cells and HepG2: VDAC1/2, 2/3,1/3 KO
cells, were generous gift from Dr. Jack Wands, Brown University, Providence, RI, and
Dr. Steven Duncan, MUSC, Charleston, SC. HepG2 and HepG2 VDAC double KO cells
were grown in Eagle’s minimum essential medium (EMEM), HCC4006 cells in Rosewell
Park Memorial Institute (RPMI) 1640. Huh7 cells were grown in EMEM with the
addition of 1% 100X MEM Nonessential amino acids. For all cancer cell lines, media
was supplemented with 10% FBS, 100 units/mL penicillin and 100 μg/mL streptomycin
and they were maintained in 5% CO2/air at 37 °C. BJ1 fibroblasts were grown in DMEM
supplemented with 0.2% FBS 3% O2 and 10% CO2. Experiments were performed with
cells at 70–80% confluency either in modified Hankś balanced salt solution (HBSS)
containing (in mM): NaCl 137, Na2HPO4 0.35, KCl 5.4, KH2PO4 1, MgSO4 0.81, Ca2Cl
0.95, glucose 5.5, NaHCO3 25 and HEPES 20, pH 7.4, or complete growth media.
Confocal microscopy of tetramethyl rhodamine methylester (TMRM) and NADH
HepG2 and Huh7 cells plated in Grenier Bio TC 4-chamber plates (Greiner-BioOne, Monroe, NC) or 35 mm MatTek dishes (MatTek Corporation, Ashland, MA) were
loaded with 20 nM TMRM for 60 min in modified HBSS. Cells incubated in modified
HBSS in a humidified 5% CO2 at 37° C were imaged with a Zeiss LSM 880 NLO
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inverted laser scanning confocal microscope (Thornwood, NY) with a 63X 1.4 N.A. plan
apochromat oil immersion lens. TMRM was excited at 561 nm and emission signal was
detected with a Quasar multichannel spectral detector at 590–610 nm through a one Airy
unit diameter pinhole. TMRM intensities were quantified to make relative comparisons
using Photoshop CS4 software (Adobe Systems, San Jose, CA) as previously described
[87, 186]. A minimum of 4 randomly selected fields with 8-20 cells per field were
imaged during the time course of 3 independent experiments for all microscopy
experiments.
NADH autofluorescence was imaged using multiphoton laser excitation (720 nm,
3% power) and an infrared-blocking emission barrier filter (460 ±25 nm). TMRM and
NADH intensity were quantified using Zeiss Zen and Photoshop CS4 (Adobe Systems,
San Jose, CA) software after subtraction of background fluorescence as described in
[187].
Live Cell Respirometric assays
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR)
were measured using a Seahorse XF96 analyzer (Agilent Technologies, Santa Clara, CA)
and calculated from the continuous average slope of the O2 partitioning among plastic,
atmosphere, and cellular uptake (37, 38). SNU449, Huh7(18,000/ well) or HepG2 cells
(25,000/ well) in XF 96 well microplates were maintained in growth media and treated 24
h after plating. Experiments were performed in 200 µL/ well of a buffer containing (in
mM): L-glutamine 4, D-Glucose 10, sodium pyruvate 1, CaCl2 0.036, MgCl2 0.06,
KH2PO4 0.05, KCl 0.54, Na2HPO4 heptahydrate 0.05, HEPES 2 and NaCl 13 (pH: 7.4).
Microplates and sensor cartridges were kept in an air incubator for 1 h before
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experiments. Basal, oligomycin sensitive, and maximal respiratory capacity were
determined after sequential addition of OLIGO (1µM), CCCP (1 µM), and rotenone (2
µM) + antimycin A (2 µM), respectively.
Measurement of cellular superoxide production
To assess mitochondrial superoxide production, we loaded cells with MitoSOX
Red (2.5 μM) for 5 min in modified HBSS before washing out. MitoSOX Red was
excited in cells maintained in HBSS using a 488-nm laser. Emission was measured at
560–600 nm. At least 4 fields with 8–10 cells per field were imaged during the time
course of 3 independent experiments. Quantification of MitoSOX relative fluorescence
was assessed as described for TMRM using Photoshop CS4.
Confocal microscopy using annexin V and propidium iodide
For cell death imaging, cells were loaded with Hoescht (0.5 μg/ml), annexin V
(1:150, vol:vol) and propidium iodide (PI) (30 μM) in HBSS for the duration of the
experiment. Hoescht was excited at 405 nm and detected at 426–440 nm; annexin V was
excited at 488 nm and detected at 493–584 nm, whereas PI was excited at 561 nm and
detected at 595–718 nm. Fluorescent polystyrene microspheres (4 μm) (MultiSpeck
Multispectral Fluorescence Microscopy Standards Kit M-7901, Molecular Probes,
Invitrogen, Carlsbad, CA) were used as fiducial markers. Microspheres diluted in HBSS
were added to TMRM loaded cells at a final concentration of 30,000 microspheres/ml.
Images were taken after sedimentation of the microspheres.
Quantification of ATP
ATP was determined in cells lysed with the luciferase-based CellTiter-Glo
Luminescent Assay Kit (Promega, WI, Cat # G7570). Luminescence (in relative light
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units) was measured in a Biotek Synergy H1 plate reader. All luminescence values were
normalized per million cells and expressed as percentage compared to vehicle.
Western blotting
HepG2 and Huh7 cells were lysed in RIPA buffer containing 50 mM Tris, 150
mM NaCl, 1% sodium deoxycholate, 1 mM ethylene glycol, bis (2-aminoethyl ethyl)
tetraacetic acid (EGTA), 0.1% sodium dodecyl sulfate 1% Triton X-100) pH 7.4, in the
presence of protease and phosphatase inhibitors. Protein concentration was quantified
with a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Rockford,
IL). Proteins were separated using 4–12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), transferred onto polyvinylidene difluoride membranes
(Millipore Sigma, Burlington, MA) and blocked with 0.5% BSA for 1h. Blots were
probed with antibodies against p-JNK (1:500, vol:vol) or total JNK (1:500, vol:vol) at
4°C overnight. Membranes were subsequently washed in Tris-buffered saline pH 7.4 with
0.1% Tween 20, and incubated with the corresponding horseradish peroxidaseconjugated secondary antibodies (1:5000 vol:vol) at room temperature for 1 h. Protein
bands were detected using the Pierce ECL Western Blotting Substrate. Intensity of the
bands normalized to β-tubulin was quantified using a LI-COR Odyssey Blot Imager (LICOR Biosciences, Lincoln, Nebraska).
Proximity ligation assay (PLA)
Cells were grown on 10-well chamber slides (Ibidi, Fitchburg, WI) for 48 h. PLA
was performed with Duolink® In Situ Detection Reagents Far Red (Sigma Aldrich)
following the manufacturer’s instructions. Cells were treated with primary antibodies
anti-pJNK (Cell Signaling Technology, 1:100, rabbit) and anti-TOM20 (Santa

33
Cruz,1:100, mouse). For negative control experiments only one antibody at a time was
incubated with the PLA probes. Slides were mounted using Duolink in situ Mounting
Medium containing DAPI. Images were taken using a Zeiss LSM 880 confocal
microscope. Proximity ligation assay z-stacks were captured with sections spanning
entire cells. Zeiss software Blue edition was used to obtain maximum intensity
projections and cross-sections of the confocal images. The threshold was set
automatically using ImageJ 3D Objects Counter for each image and kept constant within
each set of experiment. Quantification of signals (number of dots per cell) was obtained
after thresholding using ImageJ, and normalized to vehicle. Four z-stack images per
experimental conditions analyzed.
Virtual screening
We used a virtual screening strategy to identify novel compounds targeting the
NADH-binding pocket. We chose an NMR structure of VDAC (PDB: 6TIR), solved with
NADH bound within the pore among the 12 X-ray or NMR structures resolved for
VDAC [176]. NADH binding reduces the conductance of the pore sterically without
triggering a structural change. We used the NADH pocket for the virtual screening of the
South Carolina Compound Collection SC3 comprised of over 130,000 compounds,
including 100,000 proprietary and fully annotated drug-like molecules. To optimize the
screen, we used the nicotinamide moiety and adjacent phosphate groups that is resolved
in a well-defined pocket to generate shape-based queries, while omitting the adenosine
moiety that freely rotates within the channel. The shape-based virtual screening, using the
OpenEye software ROCS (OpenEye Scientific Software, Inc), assumes that compounds
with similar shape and electrostatic characteristics bind to similar targets. Molecular

34
docking of the top 20,000 compounds was performed using the extra precision (XP)
scoring function against VDAC 1 (Glide; Schrodinger Inc). The top 500 scoring
compounds were identified based on the lowest scoring docking energy and visually
inspected form which, 72 compounds were selected for physical screening using ΔΨm as
a readout of mitochondrial metabolism.
Expression and purification of recombinant human VDAC 1
pET-29a recombinant human VDAC1 (rhuVDAC1) Open Reading Frame (ORF)
clone plasmid construct, was purchased from GenScript and confirmed using sequencing.
The plasmid was transformed into expression strain BL21 (DE3) (ThermoFisher) bacteria
grown in Luria-Bertani media containing 50 µg/mL Kanamycin. The expression of the
His-tagged rhuVDAC1 was induced by 1mM isopropyl-β-d-thiogalactopyranoside
(IPTG) for 4 h at 37º C with vigorous shaking. Bacteria were then harvested by
centrifugation at 6000 rpm at 4º C for 10 min. The biomass (6-7 g/L) obtained was
resuspended in buffer A (1:50 v/v, 20mM Tris, pH 7.9, 200mM NaCl, 1 mM
phenylmethylsulfonyl fluoride (PMSF), EDTA free 1X protease inhibitor cocktail).
Resuspended bacteria were incubated with 0.5 mg/mL of lysozyme on ice for 30 min and
lysed by pulse sonication. Inclusion bodies were washed in buffer A before solubilizing
in buffer B (1:20 v/v, 4 M guanidine–HCl, 20 mM Tris–HCl, pH 7.9, 500mM NaCl, and
10% glycerol) at 4º C for 30 min with gentle stirring. The supernatant containing the
denatured rhuVDAC1 was collected by centrifugation at 15,000 g for 30 min. Buffer B
(containing ̴ 20 mg total soluble proteins) was incubated with 1 mL of NickelNitriloacetic acid (Ni-NTA) Superflow Agarose beads; before incubation with 5 mL of
denatured protein supernatant for 2 h, followed by washing with buffer B. Further 3-step
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wash with buffer B mixed with buffer C (2% n-octyl-b-D-glucopyranoside (OG) from
CalBiochem, 20 mM Tris, pH 7.9, 500 mM NaCl, and 10% glycerol) plus 10 mM
imidazole (B:C = 1:3, 1:7, and 1:15, respectively) was performed to ensure maximal
refolding and renaturing of the protein, and to remove excessive impurity. Additional
washes with buffer C and 10 mM imidazole removed excess of guanidine, before the Histagged rhuVDAC 1 was eluted using buffer C supplemented with 300 mM imidazole
under gravity at 4 ºC. Protein fractions were dialyzed against buffer C for 4-6 h. Final
purity and identity of the desired proteins were confirmed by analyzing the bands in SDSPAGE and western blot.
Wound healing and cell cytotoxicity assays
SNU-449 cells were plated in 2-wells Ibidi Culture-inserts (Gräfelfing, Germany).
After overnight incubation, inserts were removed and cells were washed with PBS. Fresh
medium containing SC18, sorafenib, or vehicle was then added to the culture plate,
which was incubated using a humidified 5% CO2/ air at 37° C in a BIOTEK Cytation 5
multimode (imaging) reader equipped with a BioSpa automated incubator and MultiFlo
liquid handler (Agilent, CA, USA). The entire plate was imaged in a time-lapse mode
every 4 h for 2 d.
EC50. SNU-449 cells plated in glass bottom, 10-well Cellview culture slides
(Greiner-Bio-One), were incubated with 20 nM TMRM in HBSS for 1 h. EC50 was
calculated assessing mean intensity of TMRM fluorescence (GraphPad Prism, San Diego,
CA) after 2 h exposure to SC18 at increasing concentrations.
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LC50. SNU-449 cells plated in 6 well tissue culture plates (VWR, Radnor, NC)
were exposed to SC18 at increasing concentrations for 5 d. Cell viability was determined
using a trypan blue exclusion assay and calculated using GraphPad Prism.
Cell viability assays
The PI cell killing assay was done as described before (29, 39). Briefly, cells
plated in a 4-well plate format were incubated in HBSS with PI (30 μM) for 30 min. PI
was excited at 530 nm (25 nm band pass) with emission collected at 590 nm (40 nm band
pass) using a Novostar plate reader (BMG LABTECH GmbH, Offenburg, Germany).
After baseline (A), PI fluorescence was measured every hour (X). To avoid temperature
fluctuations, plates were placed in 5 % CO2/air at 37° C between measurements. At the
end of the experiments, digitonin (100 μM) was added to label all the nuclei with PI and a
final fluorescence reading was collected after 20 min (B). Percentage of dead cells (D)
was calculated as D=100(X-A)/(B-A).
Cell cycle synchronization
HepG2 cells were plated in 6-well plates (CytoOne) at 300k cells/well for flow
cytometry and, in parallel, in 4-chamber dishes (Greiner) at 250k cells/well for imaging.
Both sets of cells were treated equally. For synchronization in G0/G1, cells were grown
in whole media for 48 h followed by serum-free media for another 48h. For
synchronization in S phase, cells were grown for 48 h in growth media, before adding
thymidine (2 mM) for 24 h. After thymidine, cells were rinsed with warm PBS and
exposed to 2-deoxycytidine (24 μM) for 9 h, before exposure to a second thymidine (2
mM) block in whole media for 24 h. Cells were released from the second thymidine
block by rinsing with PBS and adding fresh media for 6 h. For synchronization in G2/M,
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cells were exposed to a double thymidine block followed by exposure to nocodazole (100
ng/mL) for 20 h. After cell cycle synchronization was confirmed by flow cytometry
analysis, cells plated in 4 chamber dishes were loaded with TMRM and imaged as
described in 2.3.
Flow cytometry analysis
Analysis of cell cycle progression was determined after cells were fixed with pure
ethanol at 4°C for 1 h, washed with PBS, and incubated with FxCycle ™ PI/RNAse
Staining Solution per manufacturer’s instruction for 30 min at room temperature. Cell
size was assessed using forward and side scatter plots on the collection software BD
FACSDiva. Debris and aggregates were excluded. PI uptake was analyzed by
fluorescence-activated cell sorting on flow cytometry (Fortessa X-20). PI absorbance was
plotted on a histogram and the percentage of cells in each phase of the cell cycle was
assessed using ModFit LT 5.0.
Creation of VDAC isoform specific cell lines
sgRNA sequences targeting Exon 4 of VDAC 1, Exon 5 of VDAC2 and Exon 5
of VDAC3 were designed using Synthego (Synthego, Redwood City, CA) or CRISPOR
(http://crispor.tefor.net/) and synthesized by IDT (IDT, San Diego, CA). sgRNA sense
and

antisense

strands

were:

VDAC1,

ACTAGGCACCGAGATTACTG

and

CAGTAATCTCGGTGCCTAGT;

VDAC2,

CGCGCGTCGTAAGTAAAGCT

and

AGCTTTACTTACGACGCGCG;

VDAC3,

GACCAGAAGTAGAAAATTCC

and

GGAATTTTCTACTTCTGGTC.
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Each of the guide RNA sequences were cloned into the PX459 pSPCas9(BB)-2APuro vector. For transfection, HepG2 cells were plated at approximately 50% confluence
in 10 cm tissue culture dishes. The following day, cells were transfected with 30 µg of
total sgRNA, 15 µg each, in the following combinations: VDAC1/VDAC2,
VDAC1/VDAC3, and VDAC2/ VDAC3 using Viafect (Promega, Cat. # E4981),
according to the manufacturer’s protocol. After 24 h, the media was changed to EMEM
10% FBS + puromycin 1 ug/ul for 48-72 hours, until all cells in a negative-control plate
treated with selection media were dead. Following selection, cells were maintained in
EMEM 10% FBS and allowed to grow until colonies were visible. Colonies were then
transferred into each well of a 96-well plate and allowed to grow for an additional 2-3 d.
Colonies were dissociated with trypsin and divided between two 96 well plates. After 2-3
d of growth, the wells of one plate were harvested using 50 µl QuickExtract
(QuickExtract, Middleton, WI), following the manufacturer’s instructions. Extracted
DNA was used for PCR with primers designed to amplify the target region. Forward and
reverse

primers

were:

VDAC1,

GTGCAGGCTGTGACTCTTCT

and

AAGGTCAGCTTCAGTCCACG; VDAC2, AGGGAGGAAGGAAGCTGTCTGC and
GTCACAAAGGGCTTCCACCACC; VDAC3, GCTGGTCTTGAGCTCCTGGACT and
ACCCAGGAGAAGCTTAGCTGTGT.
Following PCR amplification, the products were digested with enzymes with
recognition sites near the sgRNA cut site (VDAC1 – MboI, VDAC2 – AluI, and VDAC3
– ApoI). If CRISPR-Cas9 modification was successful, the enzyme would fail to digest
the PCR product. When potential hits were identified, PCR products of the target regions
were sequenced and ICE analysis (Synthego), was used to identify and confirm knockout.
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Absolute Quantification Specific Methods
Relative fluorescence by confocal imaging of TMRM, Rh123, and DiBAC4(3)
Cells plated in Greiner Bio TC 4-chamber plates (Greiner-Bio-One, Monroe, NC),
or 35 mm MatTek dishes (MatTek Corporation, Ashland, MA), were loaded with TMRM
(200 nM) for 30 min in modified Hank´s balanced salt solution (HBSS) containing (in
mM): NaCl 137, Na2HPO4 0.35, KCl 5.4, KH2PO4 1, MgSO4 0.81, Ca2Cl 0.95, glucose
5.5, NaHCO3 25 and HEPES 20, pH 7.4, or complete growth media. After washing,
subsequent incubations were performed using TMRM (50 nM) to maintain equilibrium
distribution of the fluorophore as described previously [1, 188]. Cells incubated in
modified HBSS in a humidified 5% CO2/air at 37° C, were imaged using a Zeiss LSM
880 NLO inverted laser scanning confocal microscope (Thornwood, NY) with a 63X 1.4
N.A. plan apochromat oil immersion lens. TMRM was excited at 561 nm and emission
detected with a Quasar multichannel spectral detector at 590–610 nm through a one Airy
unit diameter pinhole. Alternatively, cells were loaded with Rh123 (10 nM) and
zosuquidar (1 µM) for 90 min at 37° C in modified HBSS. Images of Rh123 were
collected using a 488 nm excitation. Cells loaded with DiBAC4(3) (500 nM) for 30 min
were imaged using a 510-540 nm band-pass filter as previously reported [23]. After
establishing steady baseline images, CCCP (1 µM) was added to trigger full
depolarization while continuously recording. This enabled calibration of the
measurements and confirmed that both TMRM and Rh123 were used in non-quench
mode. Both TMRM and Rh123 fluorescence intensities were quantified to make relative
comparisons using Photoshop CS4 software (Adobe Systems, San Jose, CA), as
previously described [189]. A minimum of 4 randomly selected fields with 8-20 cells per
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field were imaged during the time course of at least 3 independent experiments. The
mitochondrial network from individual cells were circled with Photoshop lasso tool, or
ImageJ to determine fluorescence intensity from each region of interest. Relative
fluorescence was calculated as a percentage of the highest fluorescence value of the
population. Heterogeneity was calculated by quantifying intra-experimental variances in
ΔΨm, and expressed as SD of the replicates ± SE.
Absolute and unbiased quantification of ΔΨm in cancer cells and fibroblasts
Cancer cells.
Cells were plated in glass bottom, 10 well Cellview culture slides (Greiner-BioOne) and maintained in culture medium. Absolute millivolt potentials were calculated in
single cells using time-lapse laser scanning confocal microscopy of TMRM and the ΔΨm
probe FLIPR, as described in [190] with slight modifications. A non-fluorescent DMEMbased potentiometric imaging medium (PM) modified from the original description was
prepared to assure constant TMRM and FLIPR concentrations. Briefly: 2x PM
component A DMEM powder (Image Analyst Software, Novato, CA), was supplemented
with NaCl, HEPES, and NaHCO3 (in mM: 23, 20, and 1), respectively, adjusted to pH 7.4
at 37°C. Before experiments, 2xPM was further supplemented with glucose, CaCl2,
TMRM, TPB and FLIPR (5.6 mM, 1.8 mM, 20 nM, 1 µM and 1:200), respectively. The
supplemented 2xPM was diluted 1:1 with NaCl (240 mM). The working solution (PMNa)
was used to preincubate cells for 1h. After 1h, half of the volume was replaced with fresh
PMNa. Recordings were performed with a Zeiss LSM 880 NLO inverted laser scanning
confocal microscope as described above, with wide pinhole (9.94 airy units). FLIPR and
TMRM were excited simultaneously at 488 nm (2.0% laser power) and at 561 nm
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(0.1%), and emissions were detected at 521-558 nm and 597-668 nm, respectively.
Images were analyzed using the “Mitochondrial membrane potential measurement
(TMRM/FLIPR) for confocal” pipeline (Image Analyst MKII (Image Analyst Software)).
This pipeline, that measures mean fluorescence intensities in whole cells, was slightly
modified from the generic pipeline by removal of background subtraction. Channel
registration was not required for the confocal imaging setup described here. Calculation
of ΔΨm depends on the number of mitochondria in cells, ultrastructure and probe
binding.

These

parameters

were

calibrated

for

each

cell-type,

determining

mitochondria/cell volume fractions (7.80 ± 0.05 and 5.83 ± 0.007 for HepG2 and
HCC4006 cells respectively); and apparent activity coefficient ratio (0.18 and 0.38 for
HepG2 and HCC4006 cells respectively), as previously described [191].
Plasma membrane potential was determined using the “Iterative Complete (Zero
only)” approach in the “Membrane Potential Calibration Wizard”, because stepwise
calibration of the ΔΨp by increasing extracellular potassium concentration as described
for neurons, was not possible in HepG2 and HCC4006 cells (in 7). This calibration
approach was used together with the “Complete” ΔΨm approach to determine both ΔΨp
and ΔΨm from two-channel fluorescence time courses of mitochondrial depolarization
triggered by a mitochondrial complete depolarization cocktail (MDC) containing (in
µM): 1 valinomycin, 2 oligomycin, 0.1 FCCP, 2 Antimycin A, 2 Myxothiazol; followed
by subsequent ΔΨp depolarization induced by a complete depolarization cocktail (CDC):
2% paraformaldehyde and KCl (120 mM), and gramicidin (5 µg/ml). Our results for ΔΨp
in human liver cancer cells were similar to low values of ΔΨp (~ - 22 mV) determined for
human hepatocytes [192]. To improve robustness of single-cell calibration, using the

42
above approach, we calculated the time constant of TMRM redistribution (kt) for the cell
type, and then used a uniform value to rerun the calculations using the “Complete known
k” ΔΨm approach to generate single cell potentials.
BJ1 fibroblasts
BJ1 human fibroblasts were plated in 8-well Lab-Tek chamber coverglass and
cultured in DMEM supplemented with 0.2% FBS. The PMNa composition was (in mM):
NaCl 120, KCl 3.5, CaCl2 1.3, MgCl2 1, KH2PO4 0.4, TES 20, NaHCO3 5, Na2SO4 1.2,
glucose 25 and glutamine 2, plus TMRM (10 nM), TPB (1 µM) and FLIPR (blue version,
1:300), at pH 7.4, 37 °C. Imaging was performed on a Nikon Eclipse Ti-PFS wide-field
fluorescence microscope [191]. Image analysis was performed by a modification of the
“Mitochondrial membrane potential assay (TMRM/PMPI) with post-hoc absorbance
classifier” pipeline, using automated detection of single cells based on Hoechst 33342
staining of nuclei after live cell experiments. ΔΨp and ΔΨm calibrations were performed
using “Complete with known kP (K-steps)” and “Complete” paradigms as described
[191]. The mitochondria:cell volume fraction was 4.21 ±0.02% (n=4) in quiescent BJ1
fibroblasts and an apparent activity coefficient ratio of 0.41 was used for the calculations
[190].
The standard deviation of ΔΨm measured in a cell population reflects both
intercellular heterogeneity and noise from experimental error. These two sources of
heterogeneity are independent form each other. Assuming a Gaussian distribution for
intercellular heterogeneity and experimental noise, the variances sum. ΔΨm calibration
estimates the experimental error originating from readout noise and linear fits used for
calculating calibration parameters. A corrected variance of intercellular heterogeneity
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was calculated as cell to cell ΔΨm variance subtracted from the predicted calibration
variance. This calculation cancels instrument and calibration paradigm-specific
differences between experimenters. Therefore, corrected SD (variance) values are
directly comparable between fibroblasts and cancer cell lines used in this study.
Statistical analysis
Cell cycle and comparative cell line heterogeneity data were analyzed using
Kruskal -Wallis test where the data were unequally varied and ranked according to mean
intensity categories across multiple comparisons. Similarly, Spearman correlationregression statistics was applied for linear regression plots because of unequal variance.
Student’s t-test or non-parametric equivalent was used when comparing treatments.
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Chapter 3 : VDAC Opening and Sorafenib
Activate JNK in Hepatocarcinoma Cells Leading
to mitochondrial dysfunction and cell death
Introduction
The most common malignancy of the liver is hepatocellular carcinoma (HCC).
Chemotherapeutic options for advanced stage hepatocellular carcinoma (HCC) are
limited and restricted to sorafenib (SOR) and most recently, lenvatinib [193, 194]. The
efficacy of both SOR and lenvatinib is poor [195, 196].
SOR is a multikinase inhibitor that is rather promiscuous in its blockage of a
variety of signaling pathways relevant to tumor growth and angiogenesis. These include:
vascular endothelial growth factor receptors (VEGFR 1–3), platelet-derived growth
factor-β (PDGF-β), serine/threonine-specific protein kinases Raf, and the extracellular
signal-regulated kinase ERK [197-199]. Indeed, several reports show a direct effect of
SOR on mitochondrial metabolism; including dissipation of mitochondrial membrane
potential (ΔΨm) and inhibition of ATP synthesis [200-204].
The bioenergetics of cancer cells is driven both by glycolysis and mitochondrial
metabolism. The Warburg phenotype, which is characterized by suppression of
mitochondrial metabolism and enhanced aerobic glycolysis accounts for 20–90% of ATP
formation in cancer cells [26, 119]. Beyond differences in energy production, the current
consensus is that the Warburg phenotype facilitates the generation of carbon backbones
for the synthesis of biomass (lipids, peptides, and nucleic acids) to sustain cell growth
[205-208]. Although much research effort has been directed towards inhibiting glycolysis
as an anti-cancer strategy, the past decade has seen targeting of mitochondrial
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metabolism grow tremendously in the area of novel cancer treatments [130]. Moreover,
the metabolic flexibility of tumors that switch between glycolytic and oxidative
phenotypes depends on several factors, including pharmacological interventions which
open new possibilities for developing small molecules to target mitochondria [130, 171].
Regulation of VDAC opening modulates mitochondrial metabolism and cellular
bioenergetics [185, 209]. Previously, we showed that free tubulin closes VDAC and
decreases mitochondrial metabolism. Additionally, our lab demonstrated that erastin, a
VDAC binding protein, blocks the inhibitory effect of tubulin on VDAC [87, 210, 211].
Also, a high content phenotypic screen of 50,000 small molecules performed in our lab,
revealed a series of erastin-like compounds that increase mitochondrial metabolism and
decrease glycolysis in HCC cells. The most potent erastin-like compound identified was
the quinazolinone 5-chloro-N-[4-chloro-3-(trifluoromethyl) pheyl]-2-(ethylsulfonyl)-4pyrimidinecarboxamide (X1) that first caused mitochondrial hyperpolarization and then
mitochondrial dysfunction as assessed by the loss of ΔΨm and cell death in HCC cells.
The hyperpolarizing effect X1 was dose-dependent starting at 3 μM reaching a plateau at
10 μM. Exposures to X1 longer than an hour resulted in mitochondrial depolarization
indicative of mitochondrial dysfunction [182]. In both HepG2 and Huh7 cell lines, cell
killing was not evident at 3 μM but was almost maximal at 10 μM [181]. In our study, we
chose ΔΨm as the main readout of mitochondrial dysfunction. As previously determined,
mitochondrial dysfunction after X1 was dose and time dependent. Therefore, we only
used the small molecule X1 at 10 μM to maximize mitochondrial dysfunction in the cell
lines studied here. A similar mitochondrial dysfunction has been reported for SOR [212].
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The mechanisms underlying mitochondrial dysfunction by both SOR and X1 remain
unknown.
The last tier members of the mitogen activated protein kinases (MAPK) cascade
are c-Jun N-terminal kinases (JNKs). A variety of cellular and environmental stresses
lead to phosphorylation of JNK [213]. After activation by upstream MAPK kinases
(MAPKKs), a sub-population of JNK translocates to mitochondria where it
phosphorylates the mitochondrial membrane scaffold SH3 domain-binding protein 5
(Sab) [214]. While interacting with the kinase interacting motif 1 (KIM1) of Sab,
translocated p-JNK initiates a cascade of events including phosphorylation of Bcl-xL,
release of cytochrome c from mitochondria, and suppression of respiration [215, 216].
Reactive oxygen species (ROS) activate JNK, an effect mainly mediated through
the apoptosis signaling kinase 1 (ASK1), which is responsive to mitochondrial ROS
[217]. Also, JNK activation leads to increased mitochondrial ROS formation, in a
positive feedback loop that eventually leads to mitochondrial dysfunction. Although it is
proposed that SOR causes mitochondrial dysfunction through a ROS dependent
mechanism upstream of JNK activation with the induction of ferroptosis, the role of JNK
activation in HCC cells treated with SOR remains controversial [200].
Here, we hypothesized that mitochondrial dysfunction induced by X1 and SOR is
mediated by a common mechanism involving ROS formation and JNK activation. We
showed that both X1 and SOR activated JNK and increased mitochondrial superoxide
(O2•−) production before the onset of mitochondrial depolarization. The loss of ΔΨm was
accompanied by a decrease in respiration. Mitochondrial dysfunction was prevented by
JNK inhibition and by blocking subsequent JNK translocation to mitochondria. JNK
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inhibition also prevented ROS formation induced by X1 and SOR. We also found that
mitochondrial dysfunction induced by X1 was followed by cell death.

Results
X1 and Sorafenib depolarize mitochondria in hepatocarcinoma cells
Previously, we showed that erastin and the erastin-like anti-Warburg compound
X1 promoted mitochondrial hyperpolarization followed by depolarization [181].
Recently, a drop in mitochondrial ΔΨ in HepG2 cells has also been reported after
treatment with sorafenib [218]. Here, we assessed by confocal microscopy the effect of
X1 and sorafenib on mitochondrial ΔΨ in HepG2 and Huh-7 cells using the cationic
ΔΨm-indicating fluorophore, TMRM. Mitochondria of untreated cells or after vehicle
were filamentous, heterogeneously polarized, and distributed throughout the cytoplasm as
described previously [181, 211]. X1 (10 µM) decreased mitochondrial ΔΨm by ~30%
and ~43% in Huh-7 and HepG2 respectively. Similarly, sorafenib (3 µM) depolarized
mitochondria ΔΨ by ~42% in Huh7 and by ~47% in HepG2 cells (Fig. 3-1 A-C). These
results confirm that both X1 and sorafenib cause mitochondrial dysfunction in human
hepatocarcinoma cells.
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Figure 3-1. X1 and sorafenib depolarize mitochondria.
Huh7 (A) and HepG2 cells (B) incubated in HBSS were loaded with TMRM, as described in
materials and methods. Cells (Same field) were imaged before (Baseline) (A and B, right panels)
and after treatment with X1 (10 μM, A and B, upper right) or sorafenib (3.5 μM) (A and B, lower
right) for 1 h. Fluorescent polystyrene microspheres were used as fiduciary markers (arrows).
Image intensity was pseudocolored according to the reference bar. In (C), TMRM fluorescence
was quantified after X1 and sorafenib treatments compared to vehicle. *p<0.05 from 3
independent experiments. With permission from [1].
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X1 and sorafenib decrease respiration.
The effects of X1 and SOR on respiration (assessed as oxygen consumption rate)
in Huh7 cells was determined using a Seahorse XF96 extracellular flux analyzer. Cells
were treated with vehicle (VEH), X1 (10 μM) for 30 and 60 min, or SOR (5 μM) for 30
min. SOR and X1 at 30 min decreased basal respiration by ~39% and 41%, respectively
(Fig. 3-2 A). Longer exposure to X1 (60 min) decreased basal respiration by ~64%.
Subsequent addition of OLIGO (1 μM), an ATP synthase inhibitor, decreased oxygen
consumption (Δ= OCR before-OCR after OLIGO) by ~50% after VEH, by ~29%, and
23% after X1 and SOR for 30 min and by ~8% in cells treated with X1 for 60 min. Both
X1 and SOR at 30 min decreased the maximal respiration induced by the uncoupler
CCCP, whereas 60 min treatment with X1 completely blocked uncoupled respiration.
Taken together these findings indicate an inhibitory effect of X1 and SOR on oxidative
phosphorylation that is maximal after longer exposures to X1 (Fig. 3-2 A). X1 also
decreased ECAR by ~60%, suggesting an inhibitory effect on glycolysis (Fig. 3-2 B). By
contrast, SOR slightly increased ECAR (~ 12%) suggesting a compensatory increase in
glycolysis (Fig 3-2 B).

50

Figure 3-2. X1 and sorafenib decrease cellular respiration.
Oxygen consumption rates after X1 (10 μM) and SOR (5 μM) were
determined using a Seahorse XF96 analyzer. In (A), basal respiration,
oligomycin-sensitive respiration and maximal respiration in Huh7 cells
treated with X1 for 30 min or pretreated with X1 for 60 min, and SOR for
30 min or VEH. In (B), extracellular acidification rates under the same
experimental conditions described in A. *, p < 0.05 vs. baseline from 3
independent experiments. With permission from [1].
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X1 and sorafenib activate JNK
In previous work, we showed that X1 and the VDAC-binding small molecule
erastin induce ROS production in HepG2 and Huh-7 cells [181]. Others report that p-JNK
promotes ROS production and that increased ROS activates JNK [215, 217]. Activation
of JNK by sorafenib has also been reported recently [219, 220]. Accordingly, to
determine if erastin and X1 activate JNK we treated HepG2 cells with erastin (10 µM)
and Huh7 cells with X1 (10 µM) and measured p-JNK by Western blot as a measure of
JNK activation. p-JNK progressively increased both after erastin and X1, reaching
maximal levels (~2.6-fold increase) within 30-60 min in both cell lines. Maximal
activation of JNK occurred within 60 min remained unchanged after erastin and X1 up to
3 h (Fig. 3-3 A and B, and not shown). JNK inhibition by SP600125 almost completely
blocked the increases of p-JNK without affecting total JNK (Fig. 3-3 C and D). To assess
if ROS production was promoting JNK activation after X1, we pretreated cells with Nacetyl cysteine (NAC), a glutathione precursor and ROS scavenger. Similar to JNK
inhibition, NAC partially prevented JNK activation compared to X1 alone (Fig. 3-3 C-D).
Our results indicate that, in addition to increasing ROS formation, X1 induces
phosphorylation of JNK in a time dependent manner.
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Figure 3-3. X1 induces JNK activation.
HepG2 cells in whole media were treated with erastin (10 μM) for 3 h or
X1 (10 μM) for 2 h (B, Huh7 cells). Proteins were extracted at
progressive time points, and Western blotting for p-JNK were
performed, as described in Materials and Methods. In (C), Huh7 cells
were treated with X1 (10 μM) for 30 min with and without pretreatment
with SP600125 (30 μM) for 1 h or NAC (100 μM) for 30 min before
immunoblotting for pJNK, total JNK and β-actin as a loading control. In
(D), pJNK/JNK was determined by densitometry and plotted. *p<0.05
vs vehicle, #p<0.05 vs X1 from 3 independent experiments. SP:
SP600125; NAC: N-acetyl cysteine. With permission from [1].
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JNK inhibition prevents mitochondrial depolarization induced by X1 and sorafenib
To determine if mitochondrial depolarization induced by X1 and sorafenib was
dependent on JNK activation, we pretreated HepG2 and Huh-7 cells with two structurally
unrelated JNK inhibitors, JNK inhibitor VIII (5 µM) and SP600125 (30 µM). Both JNK
inhibitors completely abrogated mitochondrial depolarization induced by X1 in Huh-7
and HepG2 cells. In Huh-7 cells pretreated with SP600125 or JNK inhibitor VIII,
mitochondrial ΔΨm remained unchanged or slightly increased after X1 whereas X1 alone
decreased mitochondrial ΔΨ by ~47% (Fig.3-4 A and B). Similarly, JNK inhibition
blocked X1-dependent mitochondrial depolarization in HepG2 cells (not shown).
Since both X1 and sorafenib depolarize mitochondria and increase ROS
generation, we also assessed the effect of JNK inhibition on mitochondrial ΔΨ after
sorafenib. Similar to X1, pretreatment with JNK inhibitor VIII prevented mitochondrial
depolarization induced by sorafenib both in Huh-7 and HepG2 cells (Fig.3- 5 A-C). Our
findings show that mitochondrial dysfunction after both X1 and sorafenib are mediated
by JNK activation.
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Figure 3-4. JNK inhibition prevents mitochondrial dysfunction induced by X1.
Huh7 cells incubated in HBSS were loaded with TMRM, as described in Materials
and Methods. A.) Images were recorded before (left panels) and after addition of
X1 (10 μM) for 1 h (upper right) with and without 1 h pretreatment with SP600125
(30 μM) or JNK inhibitor VIII (5 μM), as indicated. Image intensity was
pseudocolored according to the reference bar. In B.) TMRM fluorescence was
quantified after the various treatments. *p<0.05 vs vehicle, #p<0.05 vs X1 from at
least 3 independent experiments. SP: SP600125; VIII: JNK inhibitor VIII. With
permission from [1].
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Figure 3-5. JNK inhibition attenuates mitochondrial dysfunction induced by sorafenib.
Huh7 and HepG2 cells incubated in HBSS were loaded with TMRM. Images were collected
before (A and B, upper left panels) and after sorafenib (3.5 μM) for 30 min (A and B, upper
right panels). In separate experiments, cells were imaged after pretreatment with JNK inhibitor
VIII (5 μM) for 1 h (A and B, left lower panels) and re-imaged after treatment with sorafenib
(3.5 μM) (A and B, lower right panels), or FCCP (1 μM). Image intensity was pseudocolored
according to the reference bar. In (C), TMRM fluorescence was quantified compared to vehicle
for both cell lines.*p<0.05 vs. vehicle, #p<0.05 vs SOR from 3 independent experiments. With
permission from [1].
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JNK mediates superoxide production induced by X1 and sorafenib
Mitochondria are the major site of generation of O2•- mainly at complexes I and
III (site IIIQo) [223]. It has been proposed that O2•- formed at site IIIQo is released
equally to each side of the mitochondrial inner membrane. O2•- released to the cytosol
activates members of the MAPK family of serine/threonine kinases, especially JNKs. To
assess whether O2•- formation depends on JNK activation we pretreated cells with JNK
inhibitor VIII (5 µM) or SP600125 (30 µM) before adding X1 or JNK inhibitor VIII (5
µM) before sorafenib in cells loaded with the mitochondrial O2•-indicator MitoSOX Red.
X1 or sorafenib alone increased MitoSOX Red fluorescence by ~340% and by ~130%
respectively. JNKVIII and SP600125 blocked X1-dependent increase in MitoSOX Red
fluorescence after X1 whereas JNK VIII prevented the increase in fluorescence after
sorafenib (Fig. 3- 6 A and B). These experiments show that activated JNK mediates
enhanced

mitochondrial

O2•-

production

induced

by

X1

and

sorafenib.
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Figure 3-6. JNK inhibition blocks superoxide production induced by
X1 and sorafenib.
Huh7 cells incubated in HBSS were loaded with MitoSOX Red, as described
in Material and Methods. Images were collected after addition of vehicle
(Untreated), X1 (10 μM) and sorafenib (3.5 μM), for 1 h and 30 min,
respectively, in absence (upper panels) and presence (lower panels) of
SP600125 (30 μM) or JNK inhibitor VIII (5 μM) added 1 h before X1 or
sorafenib. In B, MitoSOX Red relative fluorescence was quantified after
treatments as compared to vehicle. *p<0.05 vs vehicle, #p<0.05 vs X1,
§p<0.05 vs sorafenib from 3 independent experiments. With permission
from [1].
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X1 induces superoxide production at Site IIIQ0
To determine major source(s) of ROS formation promoted by X1, we used a
combination of quantitative analysis of O2•−/H2O2 production at complex III and
confocal imaging of TMRM fluorescence in the presence of the specific suppressor of
site IIIQo electron leak, S3QEL 2. S3QELs are small molecules that specifically suppress
production of O2•− from site IIIQo without inhibiting oxidative phosphorylation. X1
increased the rate of formation of O2•−/H2O2 at complex III by ~22% compared to
vehicle in permeabilized Huh7 cells respiring on 5 mM succinate in an Amplex Ultra Red
assay using specific inhibitors of site IIIQo (antimycin A and Rotenone). The relatively
modest increase in the rate of O2•−/H2O2 formation (7.7 fmole/min/1,000 cells) is very
likely enough to sustain the comparatively higher increase in O2•− accumulated after X1
as determined by MitoSOX fluorescence 60 min after treatment (Fig. 3-7 A and B). The
specific role of site III in the loss of ΔΨ induced by X1 was confirmed by pretreatment
with S3QEL 2 (30 μM) that prevented mitochondrial depolarization but not
hyperpolarization after X1 (Fig 3-7 A and B). These results indicate that ROS generated
at site IIIQo are important determinants of mitochondrial dysfunction induced by X1 but
do not mediate the initial hyperpolarization after X1.
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Figure 3-7. S3QEL 2 attenuates mitochondrial dysfunction by X1.
HepG2 cells incubated in HBSS were loaded with TMRM. A.)
images were collected before (left panels) addition of X1 for 1 h (10
μM, right panels) with and without 30 min pretreatment with S3QEL
2 (30 μM, lower panels). B.) TMRM relative fluorescence was
quantified after the various treatments. *p<0.05 vs vehicle from at
least 3 independent experiments. With permission from [1].
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JNK translocate to mitochondria in the presence of X1 and sorafenib
Mitochondrial JNK signaling depends on the translocation of JNK to the
mitochondrial outer membrane where it docks on the SH3BP5 (Sab) and initiates a
cascade of cell signaling events [217]. Tat-sab

KIM1,

a peptide that selectively disrupts

mitochondrial JNK signaling, prevents JNK binding to Sab without affecting c-jun
phosphorylation. To demonstrate that the loss of mitochondrial ΔΨm induced by X1 or
sorafenib not only requires JNK activation but also JNK translocation to mitochondria
and binding to Sab we pretreated cells with the Tat-sab
KIM1

KIM1

peptide (30 µM). Tat-sab

prevented X1 and sorafenib-induced loss of ΔΨ but not mitochondrial

hyperpolarization after X1 similar to the effect of JNK inhibition (Fig. 3-8 A and B).
These results indicate that mitochondrial dysfunction after X1 and sorafenib depended
both on JNK activation and translocation to mitochondria and binding to SH3BP5.
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Figure 3-8. JNK translocation to OMM is necessary to induce mitochondria.
In (A), Proximity ligation assay. Cells were treated with X1 (10 μM) for 30 min and 60 min.
Red dots indicate proximity of p-JNK and TOM20 (distance between the two proteins < 40
nm). Nuclei stained with DAPI (blue). In (B) The number of dots/cell were quantitated
counting a minimum of 200 cells/experimental condition. Error bars represent ±SEM from
three independent experiments, *p<0.05 vs vehicle. Scale bar, 20 μm. In (C and D), Huh7
cells incubated in HBSS were loaded with TMRM, as described in MATERIAL
&METHODS. (C), cells were pretreated with Tat-sab KIM1 peptide (30 μM) for 1 h before
treatment with X1 (10 μM) (upper panels) or sorafenib (5 μM) (lower panels). Image intensity
was pseudocolored according to the reference bar. In (D), TMRM fluorescence was quantified
after the various treatments compared to vehicle. *p<0.05 vs vehicle, #p<0.05 vs X1, §p<0.05
vs sorafenib from 3 independent experiments. With permission from [1].
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X1 promotes cell death by necroptosis
It has been reported that sorafenib promotes cell killing by apoptosis [221]. To
determine the mechanism of cell death after X1 we loaded cells with annexin V as a
marker of apoptosis and propidium iodide (PI) as an indicator for the loss of integrity of
the plasma membrane that occurs in necrotic cell death. Annexin V (+) and PI (+)
labeling progressively increased 2 h after X1 (10 µM) reaching 100% of the cells 6 h
after treatment. Between 3 and 6 h after X1 cells were either Annexin V (+), PI (+) or
Annexin V+PI (+) suggesting that cells were undergoing necrosis and apoptosis. To
determine if apoptosis was followed by necrosis or the main cause of cell death was
necroptosis, in separate experiments, we inhibited the RIP1 kinase with necrostatin-1.
Inhibition of RIP-1 kinase blocked X1 induced cell death indicating that necroptosis may
be the major mechanism of cell killing (Fig. 3-9 A-B).
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Figure 3-9. X1 induces JNK-dependent necroptosis.
In (A), Huh7 cells were treated with X1 (10 μM) with and without pretreatment with
SP600125 (30 μM) for 1 h or necrostatin (NEC-1, 30 μM) for 24 h. Annexin V and
propidium iodide fluorescence was assessed as described in MATERIAL &METHODS
(In B, percentages of annexin V (+), PI (+) and annexin V+PI (+) were determined (Panel
B). With permission from [1].
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X1-dependent cell death is partially mediated by JNK
Both sorafenib and X1 have been shown to be cytotoxic for HepG2 and other
hepatocarcinoma cells in culture [181, 182, 204, 222]. To determine if cell death after X1
was dependent on JNK activation we assessed cell viability by PI fluorometry after X1 in
the presence or absence of JNK inhibitors. X1 caused ~95% cell death after 6 h whereas
in cells pretreated with JNK inhibitor VIII (5 µM) and SP600125 (30 µM) X1-induced
cell death was ~25% and ~50% respectively (Fig.3- 10).
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Figure 3-10. JNK inhibition decreases cell death after X1.
Huh7 cells were treated with vehicle (VEH), X1 alone (10 μM) or after X1 plus
pretreatment with SP600125 (30 μM) or VIII (5 μM) for 1 h. Cell death was assessed by PI
fluorometry, as described in MATERIAL & METHODS. SP: SP600125; VIII: JNK
inhibitor VIII. With permission from [1].
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Summary
These data showed that X1 and sorafenib induced persistent activation of JNK
and subsequent JNK translocation to mitochondria, leading to increased O2•- formation
and mitochondrial dysfunction in HepG2 and Huh-7 cells. JNK inhibition prevented O2•generation induced by both sorafenib and X1 and also attenuated subsequent necroptosis.
Therefore, the mechanism of action of X1 and sorafenib likely involved a positive
feedback loop of sustained, mitochondrial JNK activation and O2•- production upstream
of mitochondrial dysfunction and cell death.
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Chapter 4 : Relative and Absolute Quantitative
Analysis of Mitochondrial Membrane Potential
Heterogeneity in Cancer Cells
Introduction
The constantly changing metabolic demands of the cell require finely-tuned
mechanisms to control mitochondrial function. In non-proliferating cells, most of the
pyruvate generated from glucose is fully oxidized by mitochondrial oxidative
phosphorylation (Oxphos), that generates more than 95% of total cellular ATP [4]. By
contrast, the Warburg phenotype, which often predominates in many cancer cell types, is
characterized by enhanced aerobic glycolysis in proliferating cells while mitochondrial
metabolism varies [223-226]. The pro-proliferative Warburg phenotype favors the
formation of glycolytic intermediates not fully oxidized in mitochondria, that are used for
the biosynthesis of macromolecules [227]. The relative contribution of glycolysis and
Oxphos in cancer cells is dynamically modulated by the availability of nutrients and
oxygen, proximity to neoformed and mature blood vessels, and interaction with stromal
cells among other factors [228]. Distinct metabolic and bioenergetics patterns have been
found among patients with the same type of tumor, between primary and metastatic
tumors, and intratumorally [229, 230]. Heterogeneity of tumor metabolism and
bioenergetics, is increasingly recognized as a contributing factor for the failure of
chemotherapy [231]. Intercellular heterogeneity of mitochondrial membrane potential
(ΔΨm), reported in several cell types, [232, 233], contributes to tumor heterogeneity. The
underlying mechanisms and the adaptative relevance of ΔΨm heterogeneity in cancer
cells remain poorly understood.
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Bioenergetic adaptations to cellular requirements in cancer cells depends on the
balance between mitochondrial oxidation of respiratory substrates including pyruvate,
and the rate of glycolysis. Pyruvate, fatty acyl-CoA, glutamine and other amino acids,
that enter the mitochondrial matrix, are oxidized in the Krebs cycle, generating NADH
that, in turn, fuels the electron transport chain (ETC). The flow of electrons in the ETC to
the final acceptor oxygen, drives pumping of H+ by complexes I, III, and IV to the
intermembrane space. Proton pumping results in the generation of an electrochemical
gradient between the intermembrane space and the mitochondrial matrix, formed by an
electrical (ΔΨm) and a chemical (ΔpH) component. The electrochemical H+ gradient
drives the synthesis of ATP from ADP and inorganic phosphate (Pi) by the F1F0 ATP
synthase (Complex V), coupling electron flow in the ETC to ATP synthesis [234]. In
addition, the potential energy stored as an electrochemical H+ gradient also favors the
transport of ions and metabolites across the inner mitochondrial membrane, as well as the
import of mitochondrial resident proteins [235]. The uncoupled leak of H+ from the
intermembrane space to the matrix, is another factor influencing ΔΨm. Overall, ΔΨm, as
the main component of the electrochemical H+ gradient, is a dynamic indicator of
mitochondrial metabolism.
In live cells, most assays use lipophilic, fluorescent cations to monitor ΔΨm
[236]. The distribution of these hydrophobic cationic dyes between an external aqueous
medium and the cytosol, and between the cytosol and the aqueous compartments of
intracellular organelles, is driven by plasma membrane potential (ΔΨp) and ΔΨm,
respectively. In equilibrium, these distributions are described by their Nernstian
distribution. Therefore, in a cell with ΔΨp − 60 mV and ΔΨm: − 180 mV, a cationic dye
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would accumulate ~10 -fold in the cytoplasm and ~ 10,000 -fold within mitochondria
[237]. Fluorescence of cationic dyes is an exponential function of the differences in ΔΨp
and ΔΨm when the concentration of the dye is below the limit where self-quenching
occurs (non-quench mode). Overall, mitochondrial accumulation of a potentiometric dye,
depends on the difference in potential between the mitochondrial matrix and the external
medium. Furthermore, total probe accumulation and fluorescence intensity of ΔΨmindicating probes, including tetramethylrhodamine methyl ester (TMRM), is also a
function of geometry, binding and kinetic factors related to the dye, that contribute to the
practical quench limit [238]. In general, loading of potentiometric dyes, should be long
enough to reach an equilibrium between the mitochondrial matrix, the cytosol and the
extracellular environment [239, 240]. At present, most of the widely used experimental
approaches assess ΔΨm changes qualitatively (mitochondria are either ‘polarized’ or
‘depolarized’), or semi-quantitatively by setting an arbitrary baseline value. Recently, a
method to more accurately calculate absolute values of ΔΨm using time-lapse imaging of
TMRM fluorescence, and a ΔΨp indicator in intact cells has been reported [190, 191].
Here, we assessed intercellular differences in ΔΨm in synchronized and
unsynchronized cancer cells, and fibroblasts, using a combination of semi-quantitative
and

absolute

calibration

methods.

We

also

evaluated

changes

induced

by

pharmacological inhibition of complex III of the ETC and the ATP synthase. Our results
confirmed that heterogeneity of ΔΨm was not biased by the relative contribution of ΔΨp
and it was independent of the ΔΨm indicator dye used. We also demonstrated that ΔΨm
remained heterogeneous in synchronized cells at G1, S and G2. Inhibition of either
complex III or the ATP synthase reduced intercellular ΔΨm heterogeneity, suggesting
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that intra-mitochondrial mechanisms are major contributors to ΔΨm heterogeneity in
cancer cells.

Results
Mitochondrial membrane potential is heterogeneous in cancer cells
Relative quantification of TMRM fluorescence
Heterogeneity of ΔΨm has been previously determined by qualitative or semiquantitative methods using either confocal microscopy, or sorting by flow cytometry
[241-244]. Here, we quantitatively assessed ΔΨm as relative fluorescence of TMRM in
three human cancer cell lines of different tissue origins (HepG2 and Huh7 human
hepatocarcinoma cells; HCC4006 human lung adenocarcinoma), and BJ1 human skin
fibroblasts. In all cancer cell lines, ΔΨm was heterogeneous with marked differences in
the distribution of ΔΨm in individual cells (Fig. 4-1 A and B). The mean intensity of
fluorescence (in arbitrary units ± SE) was different for each cell line: 25.67 ± 0.95, 29.89
± 1.01, 36.32 ± 1.09, and 46.88 ± 0.69 for HepG2, Huh7, HCC4006 and BJ1 fibroblasts,
respectively. Heterogeneity of ΔΨm was calculated by quantifying intra-experimental
differences in TMRM relative fluorescence among cells. Heterogeneity of ΔΨm,
calculated as mean SD of replicates ± SE, was 19.37 ± 0.95 A.U., 19.30 ± 1.09 A.U., and
23.37 ± 1.01 A.U. for HepG2, Huh7 and HCC4006, respectively. By contrast, ΔΨm
heterogeneity in BJ1 cells was lower than all the cancer cell lines: 16.26 ± 0.69 A.U.
(Fig. 4-1 A and B). We also showed that heterogeneity was not an artifact caused by the
choice of focal planes since similar heterogeneity was observed in images taken 0.6 μm
apart from top to bottom of each cell (not shown).
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To confirm that intercellular heterogeneity of ΔΨm was an actual biological phenomenon
and not an artifact caused by the chemical behavior of TMRM, we loaded HepG2 cells
with Rhodamine 123 (Rh123), another commonly used cell-permeant potentiometric dye.
The relative quantification of Rh123 fluorescence intensity showed a similar intercellular
distribution of ΔΨm compared to cells loaded with TMRM (mean SD ± SE: 17.75 ± 1.59
A.U.) (Fig. 4-1 C and D). Our findings, in agreement with previous reports, confirmed
that ΔΨm in cancer cells is different from cell to cell and independent of the
potentiometric dye used.
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Figure 4-1.Mitochondrial membrane potential in cancer cells and fibroblasts
is heterogeneous.
HepG2, Huh7, HCC4006 cancer cells, and BJ1 fibroblasts were loaded with
TMRM or Rh123, as described in “absolute quantification specific Methods.” A.)
Red and blue arrows indicate high and low ΔΨm cells, respectively. B.) The
distribution of ΔΨm in each cell line is given as strip plots overlaid with box and
whiskers. Average SDs of the data set, used as a measure of heterogeneity, are
shown parallel (vertical) to the box. Each circle represents the relative TMRM
fluorescence of the entire mitochondrial network of individual cells. Results
represent the analysis of 1094, 524, 347, and 260 cells for HepG2, Huh7,
HCC4006, and BJ1 fibroblasts, respectively. C.) HepG2 cells loaded with Rh123
were pseudo-colored as described in Methods. D.) Strip plot overlaid with box and
whisker representing the distribution of Rh123 fluorescence intensity in HepG2
cells. Note the similar distribution of ΔΨm compared to TMRM. Rh123:
Rhodamine 123. Data from a minimum of three independent experiments.
Modified with permission.
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Simultaneous determination of mitochondrial and plasma membrane potentials
Uptake and accumulation of the cationic probes TMRM and Rh123 is influenced
by both ΔΨm and ΔΨp. Although ΔΨm is the main driver of intra-mitochondrial
accumulation of TMRM and Rh123, ΔΨp also influences the amount of each probe
accumulating in the mitochondrial matrix. To assess whether differences observed in
TMRM fluorescence among individual cells were related to intercellular differences in
ΔΨp, we co-loaded HepG2 cells with TMRM and the anionic probe bis (1,3dibutylbarbituric acid) trimethine oxonol DiBAC4(3). DiBAC4(3) remains in the cytosol
and does not enter mitochondria because of its negative charge. DiBAC4(3) fluorescence
is inversely proportional to ΔΨp [245]. The mean intensities of TMRM and DiBAC4(3)
fluorescence in wild type cells co-loaded with both dyes were 43.00 ± 3.00 A.U., and
51.31 ± 3.41 A.U., respectively. The distribution of relative fluorescence of TMRM and
DiBAC4(3) was heterogeneous for each dye but did not correlate (R2 = 0.04) (Fig. 4-2 A
and B).
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Figure 4-2. Heterogeneity of ΔΨm is not driven by intercellular differences in ΔΨp.
A.) HepG2 cells were co-loaded with DiBAC4(3) and TMRM, as described in Material
and Methods. B.) Distribution of TMRM fluorescence and DiBAC4(3) fluorescence
values showed no correlation between the heterogeneity of ΔΨm and differences in
plasma membrane potential. TMRM: tetramethylrhodamine methyl ester; DiBAC4(3): bis
(1,3-dibutylbarbituric acid) trimethine oxonol, A.U: arbitrary units. Data from a minimum
of three independent experiments. With permission.
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Quantification of TMRM fluorescence in absolute values
To further confirm that heterogeneity of relative TMRM fluorescence was
genuinely reflecting intercellular differences in ΔΨm and not differences in ΔΨp, matrix
to cell volume ratios, or differential affinities for non-mitochondrial binding between cell
types, we calibrated single cell fluorescence to absolute mV. We used an internal
calibration paradigm based on a mathematical modeling of cationic and anionic dyes
distribution kinetics [246]. We recorded fluorescence time courses (not shown) of the
calibration paradigm in HepG2, HCC4006 cancer cells or BJ1 fibroblasts co-loaded with
the anionic bis-oxonol type fluorescent ΔΨp indicator (FLIPR) and TMRM (Fig. 4-3 and
not shown).
Absolute quantification of ΔΨm in HepG2 and HCC 4006 cells showed a
remarkable similar pattern of heterogeneity compared to the relative fluorescence
quantification (Fig. 4-3 A and B compared to Fig. 4-1 A and B). The distribution of ΔΨm
was similar in HepG2 (mean: - 131.33 ± 10.37 mV), HCC4006 (mean: - 148.79 ± 11.65
mV) and BJ1 cells (mean: -131.68 ± 2.47) (Fig. 4-3, A and B, and not shown).
Heterogeneity of ΔΨm, calculated as described in 3.1.1, was: 20.73 ± 3.33 mV, 23.30 ±
4.03 mV, and 11.04 ± 1.18 mV in HepG2, HCC4006 and BJ1 fibroblasts, respectively
(Fig. 4-1). The mitochondrial complete depolarization cocktail (MDC, see Methods),
depolarized mitochondria by ~ 90%. Subsequent addition of complete depolarization
cocktail (CDC, see Methods) completely depolarized plasma and mitochondrial
membranes allowing reliable calibration of subsequent parameters as described (Fig. 4-3
D) [16]. Thus, absolute single cell calibration of ΔΨm, that is not biased by ΔΨp, cell
size, background and autofluorescence, showed similar intercellular heterogeneity as
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compared to semi-quantitative relative fluorescence analysis. As it was observed using
TMRM and DiBAC4(3), the absolute quantification of ΔΨm and ΔΨp using TMRM and
FLIPR, did not show correlation between the extent of heterogeneity observed in ΔΨm
and that contributed by ΔΨp (R2 = 0.1) (Fig.4- 3 C).
Taken together, our results show that ΔΨp, although a contributing factor, is not a
major driver of ΔΨm heterogeneity. We also showed that the distribution of ΔΨm was
similar between relative TMRM fluorescence and absolute quantification of ΔΨm.
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Figure 4-3. Mitochondrial membrane potential in absolute (mV) values differ intercellularly.
Time-lapse recordings of baseline TMRM fluorescence, TMRM decay during mitochondrial
depolarization, and FLIPR accumulation after complete depolarization in HepG2 and HCC4006
cells were performed as described in Materials and Methods. A, Images of both cell lines coloaded with TMRM and FLIPR. B, Heterogeneity of ΔΨm shows intercellular heterogeneity for
each cell line. C, Correlation coefficient between absolutes values of ΔΨm and ΔΨp indicates that
heterogeneity of ΔΨm does not correlate with the ΔΨp in HepG2 cells. D, Mitochondrial
depolarization was initiated with MDC as described in Material and Methods, followed by
complete depolarization with CDC, which allowed for calibration of the system. TMRM:
tetramethylrhodamine methyl ester. Data from a minimum of three independent
experiments. #p < .05. Modified with permission.
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Mitochondrial membrane potential during cell cycle progression
Cancer cells maintained in growth media are unsynchronized. At any given
moment, most cells are either in G1, G2, and S phases, with few cells undergoing mitosis.
Accumulating evidence indicates that mitochondria change during the cell cycle, and that
mitochondrial metabolism and cell cycle progression are coordinately regulated [247,
248]. Therefore, we investigated if heterogeneity of ΔΨm observed in cell cultures could
be caused by the cell cycle progression. To determine the relationship between each
phase of the cell cycle and ΔΨm, we first synchronized HepG2 cells in either G1, S or G2
(Fig. 4 A). In parallel, both unsynchronized and synchronized cells were loaded with
TMRM (Fig. 4 B). Similar to unsynchronized cells, the spread of TMRM fluorescence
was broad in G1, S, and G2, with a shift in the median distribution of ΔΨm (mean
intensity of fluorescence compared to unsynchronized cells in A.U.): unsynchronized:
10.96 ± 0.613; G1: 10.75 ± 3.60, S: 14.51 ± 7.91, G2: 10.44 ± 2.46) (Fig. 4-4 C).
Heterogeneity of ΔΨm, expressed as mean SD ± SE, remained similar across the
different phases of the cell cycle: 7.02 ± 0.19, 6.66 ± 2.46, 6.24 ± 2.93 and 6.50 ± 0.49 in
unsynchronized, G1, S and G2, respectively. We also determined the relative contribution
of high (top 25 percentile of the whole population), intermediate and low (bottom 25
percentile of the whole population) ΔΨm cells to the shift in the median distribution of
ΔΨm observed in the whole cell population in the different phases (not shown).
Compared to unsynchronized HepG2 cells, populations arrested in G1 phase had less
high ΔΨm (12.6% vs 26.1% cells), more low ΔΨm (25.7% vs 12.6%) (p < 0.05), and
similar percentages of cells with intermediate ΔΨm. Cells arrested in S phase showed less
cells with intermediate ΔΨm (48.3% vs 61.3%), more low ΔΨm cells (28.5% vs 12.6%)
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(p < 0.05), and similar percentages of cells with high ΔΨm. Cells arrested in G2 showed
a slight increase in cells with low ΔΨm (17.3% vs 12.6%), a slight decrease in cells with
high ΔΨm (24.7% vs 26.1%)(p > 0.05), and similar intermediate ΔΨm (58% vs 61.3%),
(p > 0.05). Our results showed that ΔΨm remains heterogeneous in different phases of the
cell cycle with a gradual increase in the proportion of cells with high ΔΨm from G1 to
G2 phases.
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Figure 4-4. Mitochondrial membrane potential heterogeneity is maintained throughout the
cell cycle.
Mitochondrial membrane potential heterogeneity is maintained throughout the cell cycle. HepG2
cells were synchronized in G1, S, and G2 phases by flow cytometry, as described in Material and
Methods. A, Flow cytometry gates for G1, S, and G2 indicating the proportion of cells in each
phase. B, Images of cells loaded with TMRM were pseudo-colored according to the reference
bar, as described in Figure 1. C, Distribution of TMRM fluorescence for each phase of the cell
cycle with the average SD indicating heterogeneity (vertical bar next to the whiskers). Note that
heterogeneity of ΔΨm was maintained throughout the cell cycle. Data from a minimum of three
independent experiments. p < .05.
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Mitochondrial response after inhibition of oxphos and ATP synthesis
To investigate if basal ΔΨm influences the response to drugs inhibiting the
respiratory chain or the synthesis of ATP, we treated HepG2 and Huh7 cells with either
oligomycin (OLIGO) or antimycin A. OLIGO is a specific inhibitor of the ATP synthase
and antimycin A, an inhibitor of complex III of the ETC. OLIGO decreases the utilization
of H+ for ATP synthesis increasing the electrochemical H+ gradient thus hyperpolarizing
mitochondria. Inhibition of complex III by antimycin A, stops H+ pumping at this site,
resulting in mitochondrial depolarization. Importantly, in the presence of antimycin A,
ΔΨm is partially maintained by the ATP synthase working in reverse to hydrolyze
glycolytic ATP. We assessed changes in ΔΨm, both by relative and absolute
quantification of TMRM fluorescence after OLIGO or antimycin A (Fig. 4-5 and 4-6). In
both HepG2 and Huh7 cells, the magnitude of the increase in TMRM fluorescence in
response to the hyperpolarizing effect of OLIGO (2 µM), was inversely correlated to
basal values of ΔΨm (R2 = 0.49 for HepG2 and 0.64 for Huh7) (Fig. 4-5 A and B). After
OLIGO, relative ΔΨm increased by ~ 24% in HepG2 (baseline: 18.82 ± 0.15 A.U.,
OLIGO: 24.75 ± 0.34 A.U.) (Fig. 4-5 C), and by ~ 33% in Huh7 (5.3 ± 1.48 A.U.,
OLIGO: 7.95 ± 0.43) (not shown). Heterogeneity of relative TMRM fluorescence for
individual HepG2 cells, expressed as the average SD ± SE, was 25.34 ± 1.68 A.U. and
16.50 ± 1.18 A.U. before and after OLIGO. Calculation of ΔΨm in mV also showed an
increase of ~19% after OLIGO in HepG2 cells (baseline: - 131.33 ± 10.37 mV; OLIGO: 161.60 ± 7.56 mV, p< 0.05). The distribution of TMRM intensities after OLIGO was
shifted towards higher ΔΨm values: (baseline: 20.73 ± 3.34 mV, after OLIGO: 16.65 ±
3.92 mV), in HepG2 cells. (Fig. 4-5 C and D).
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Figure 4-5. ATP synthase inhibition increases ΔΨm and decreases heterogeneity.
A, HepG2 and Huh7 cells loaded with TMRM, as described in Material and Methods, were
imaged before (baseline), and after treatment with oligomycin (OLIGO, 2 µM) for
30 minutes. B, Single-cell relative fluorescence after OLIGO was calculated as -fold increase
compared to the basal value of TMRM fluorescence. C, Heterogeneity of relative TMRM
fluorescence for individual HepG2 cells before and after OLIGO. D, Heterogeneity of ΔΨm
in mV before and after OLIGO in HepG2 cells. The response to OLIGO was proportionally
higher in low ΔΨm compared to high ΔΨm cells. Data from a minimum of three independent
experiments. #p < .05, N.S: non-significant
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Figure 4-6. High vs low ΔΨm cells respond differently to ETC and ATP synthase inhibition.
A, HepG2 cells loaded with TMRM, as described in Material and Methods, were imaged before
and after treatment with antimycin A (2 µM) for 30 minutes. B, Single-cell relative fluorescence
was calculated as -fold decrease compare to basal TMRM fluorescence. C, Heterogeneity of
relative TMRM fluorescence for individual cells in arbitrary units. D, Heterogeneity of ΔΨm in
mV. Note that the magnitude of the response to antimycin A was slightly correlated to the basal
level of ΔΨm. Data from a minimum of three independent experiments. #p < .05
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The decrease in ΔΨm promoted by Antimycin A (2 µM) in HepG2 cells was also
correlated to the basal level of ΔΨm (R2 = 0.14), being more pronounced in cells with
high basal ΔΨm (Fig. 4-6, A and B). Determination of absolute ΔΨm confirmed the
results obtained by quantification of relative TMRM fluorescence (Fig. 4-6 C).
Antimycin A depolarized mitochondria by ~ 45% as assessed by relative fluorescence
(Baseline: 27.00 ± 1.43 A.U., antimycin A: 14.89 ± 2.59 A.U.) (Fig. 4- 6 C), and by
~19% in absolute ΔΨm (Baseline: - 151.78 ± 18.27 mV, antimycin A: - 122.38 ± 14.02
mV) (Fig. 6 D). Antimycin A decreased heterogeneity of ΔΨm: 17.34 ± 0.64 A.U. vs
9.86 ± 2.51 A.U., and 17.84 ± 3.92 mV vs to 13.40 ± 4.14 mV), before and after
antimycin A, respectively. Addition of OLIGO before antimycin A reduced heterogeneity
even more from 19.81 ± 0.58 A.U. at baseline to 5.3 ± 0.15 A.U. after antimycin A,
indicative of a contribution of ATP synthase reverse activity in the maintenance of ΔΨm.
Our results indicated that the activity of the ETC and the ATP synthase are major
contributors to the maintenance of intercellular heterogeneity of ΔΨm in cancer cells.
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Summary
Here, we confirmed intrinsic intercellular variations in ΔΨm, using a dual
approach by quantifying relative fluorescence in combination with the assessment of the
absolute ΔΨm at the single cell level. The method utilized to calculate ΔΨm in mV using
fluorescence imaging allows an unbiased quantification of absolute values of ΔΨm in
individual cells [16,24,18]. Until now, most studies involving ΔΨm-indicating
fluorophores failed to consider important variables that impact accurate interpretation of
the chemical behavior of potential-indicators dyes. Fluctuations in ΔΨp, the matrix to cell
volume ratio, the dye binding affinity and spectral shifts upon binding in the
matrix/cytosol may cause differences in fluorescence independently of the intrinsic
regulation of ΔΨm [41,21].
Formation and maintenance of ΔΨm in cancer cells depends on several factors
including the ingress of respiratory substrates to mitochondria, the activity of the ETC,
the demand of ATP, and the balance between mitochondria generated ATP and glycolytic
ATP among others. Here, we showed that intercellular heterogeneity of ΔΨm, mainly
driven by intramitochondrial factors, may eventually become a key parameter to
understand differences in metabolism among cells of the same genetic background. The
study of heterogeneity of ΔΨm may lead to new research avenues to better understand
tumor heterogeneity as well as to the identification of pharmacological targets to
modulate mitochondrial metabolism in different tumor subpopulations.
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Chapter 5 : Fast Determination of Mitochondrial
Metabolism and Respiratory Complex Activity in
Permeabilized and Intact Cells
Introduction
Mitochondria are the major cellular source of ATP in non-proliferating cells, and
relatively minor contributors to ATP production in several cancers that display a Warburg
phenotype [19, 21, 171]. In addition, mitochondria are essential for redox and ion
homeostasis, biosynthesis of macromolecules, generation of reactive oxygen species,
cellular signaling and apoptosis [161, 249, 250]. Respiratory substrates are catabolized in
the Krebs cycle to generate NADH and FADH2 that are donors of electrons entering the
ETC at complex I, to initiate oxidative phosphorylation. The subsequent flow of electrons
through complexes II, III and IV to the final acceptor O2, promotes pumping of protons to
the IMS at complexes I, III, and IV, to generate a negative ΔΨm. In the coupled
respiration, protons from the IMS are used by complex V to generate ATP from ADP and
inorganic phosphate. Thus, NADH generation, respiration (oxygen consumption), and
ΔΨm, are dynamic readouts of mitochondrial metabolism that accurately reflect
mitochondrial bioenergetics [251]. A thorough assessment of mitochondrial function is
multidimensional, time consuming, and usually requires expensive equipment and
specific training. A method to study respiratory complex activities in live cells is
currently missing. Individual respiratory complexes have been studied by Western
blotting, or by assessing activity in purified complexes, isolated mitochondria or
permeabilized cells, out of the multi-regulatory intracellular milieu. However, the amount
of each complex does not necessarily correlate with activity, and determinations of
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substrate utilization during oxidative phosphorylation do not differentiate activities of
individual complexes. Measurement of the oxygen consumption rate (OCR) is a method
of choice to study mitochondrial respiration and mitochondrial dysfunction [252-254]. In
the last decade, the Seahorse technology has been widely adopted to assess basal,
maximal and ATP-linked respiration in adherent cell cultures and isolated mitochondria
[255, 256]. Seahorse XF Analyzers are sensitive, robust, medium-throughput, and less
labor intensive compared to traditional Clark-type oxygen electrodes [257]. Here, we
describe a novel, combined approach to sequentially assess the electron flow through
respiratory complexes I-IV in permeabilized and intact cells using Seahorse technology
(Fig. 5-1). The Seahorse analysis is complemented by a highly sensitive and fast method
to assess ΔΨm and NADH using plate reader assays (Fig. 5- 2 and 3). Our combined
method allows a relatively inexpensive and fast determination of ΔΨm, NADH, and O2
consumption, major readouts of global mitochondrial function, in a few hours using
equipment frequently available in laboratories worldwide.

Materials
All solutions are prepared with ultrapure water. Reagents are analytical grade. Unless
otherwise indicated, solutions are pH 7.4, filtered and stored at 4 °C for 6-8 weeks. The
instruments needed are a Seahorse Extracellular Flux (XFe96) analyzer (or similar), and a
microplate reader, preferably with spectral scanning capabilities, and CO2/ Temperature
control (see Note 1).
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Biological buffers for respirometry
Permeabilized cells
a. 3X Mitochondrial Assay Solution with bovine serum albumin (MAS-B): 3X MAS-B
contains (mM): KH2PO4 30, sucrose 210, mannitol 660, HEPES 20, EGTA 3,
MgCl2 15; and fatty acid-free bovine serum albumin (BSA) 0.9% (w/v). Adjust pH
with KOH, filter and sterilize, Store at 4 °C (See Note 2).
b. MAS-BP: to 1X MAS-B, add FCCP (4 µM), sodium pyruvate (10 mM), malate (2
mM), and Plasma Membrane Permeabilizer (PMP) (3 nM). Use immediately at 37
°C (See Note 3).
Intact cells
a. Solution 1: 10X calcium free electrolyte buffer, contains (mM): MgCl 0.6, KH2PO4
0.5, KCl 5.33, Na2HPO4 · 7H2O 0.5, and NaCl 130; Solution 2: CaCl2 50X (1.8 mM)
(See Note 4).
b. Respiratory Medium (RM): add ultrapure water to solutions 1 and 2 to make a 1X
solution. Supplement with L-glutamine (4 mM), glucose (5.5 mM), insulin (100
nM), and fatty acid free BSA (0.3%) (See Note 5).
Potentiometric medium (PM)
Make complete PM by adding TMRM (20 nM) and zosuquidar (1µM) to HBSS
containing (mM): NaCl 137, Na2HPO4 0.35, KCl 5.4, KH2PO4 1, MgSO4 0.81, CaCl2
0.95, glucose 5.5, NaHCO3 25, and HEPES 20. Use the same day of the experiment.
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Methods: Assessment of respiratory complex activity
Permeabilized Cells
a.

Plate cells overnight in a Seahorse XFe96 Cell Culture Microplate (50-60 x 103

cells per well are optimal for 70- 90% confluency monolayers in several cell types).
Use whole growth media appropriate for the particular cell line grown at 37 °C in 5%
of CO2/air. Growth conditions may vary depending on the cell line, but will not affect
the assay.
b.

Immediately prior to the experiment, prepare 1X MAS-B. Keep it at 37 °C.

c.

Replace growth media with 175 µl 1X MAS-B incubation medium per well. Place

in a 37 °C air incubator for 1h (See Note 7).
d.

Prepare MAS-BP. Keep it at 37 °C.

e.

Setup Seahorse assay protocol for 3 reads with 0.5 min mixing time, and 3 min

measure (See Note 8).
f.

Load Seahorse cartridge ports with 25 µl of each ETC inhibitor/substrate (mM)

dissolved in MAS-BP: rotenone 0.032, succinic acid 100, antimycin A 0.016, and
ascorbate 100 + tetramethyl-p-phenylenediamine (TMPD) 1.0, to ports A. B. C, and
D, respectively (See Note 9).
g.

Replace incubation medium with MAS-BP, assemble the Seahorse cartridge and

start the assay immediately.
h.

Normalize results using BCA protein concentration (See Note 10).

i.

Analyze results (oxygen consumption rate) using the XFe Wave software

(Seahorse Bioscience Inc., MA).
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Intact cells
a.

Same as in 3.1.1. a.

b.

Immediately prior to the experiment, prepare 1X RM and warm in a 37 °C water

bath.
c.

Replace growth media with 175 µl 1X RM incubation medium per well. Place in

a 37 °C air incubator for 1h.
d.

Setup Seahorse assay protocol to allow 3 reads, 2 min mix and 3 min measure per

injection.
e.
of

Load Seahorse cartridge ports with 25 µl
each

ETC

inhibitor/substrate

(mM)

dissolved in 1X RM: rotenone 0.032,
succinate-NV

1.6,

antimycin

A

0.016,

ascorbate 100 + TMPD 1.0, to ports A, B, C
and D, respectively. (See Note 11).
f.

Replace half of the volume of 1X RM
incubation medium with fresh 1X RM. After
calibration, start the assay.

g.

Scheme 5-1. Assessment of ETC
individual complexes.

Normalize results by protein concentration

or cell number (See Note 10).

Determination of mitochondrial membrane potential
a. Plate cells overnight for a 70- 90% confluent monolayer in a black wall, glass
bottom, 96 –well, tissue culture treated plate. Use whole growth media. Typically,
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70-80 x 103 cells per well are optimal for several cell types. Leave 3 wells without
cells for TMRM background subtraction.
b. Prepare PM. Keep it at 37 °C.
c. Remove growth media from 96 well plate gently, washing immediately with PM
three times.
d. Incubate cells in PM for 60 min at 37 °C in 5% of CO2/air (See Note 12).
e. Perform a spectral scan of TMRM fluorescence using a microplate reader to
determine appropriate excitation/emission of TMRM in PM (See Note 13).
f. Replace half of the incubation media with fresh PM and start fluorescence
acquisition in the plate reader at excitation/emission 570/590 nm. If optimal
wavelengths identified in the spectral scan differ from the 570/590, use those
found with the available equipment (See Note 14).
g. Start the assay.

Determination of cellular NADH content
a. Plate cells same as described for mitochondrial membrane potential. Leave wells
without cells to make a β-NADH standard curve.
b. Prepare HBSS as described in Step 2.2. without TMRM and zosuquidar. Keep it at
37 °C.
c. Remove growth media gently. Wash three times with HBSS.
d. Incubate cells in HBSS for 30 min at 37 °C in a 5% of CO2/air.
e. Perform a spectral scan of NADH auto-fluorescence using a microplate reader to
determine

appropriate

excitation/emission

of

NADH

in

HBSS.

excitation/emission at 360/430 nm or similar as identified in the spectral scan.

Use
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f. Dissolve β-NADH in HBSS and make a serial dilution (0 to 3 mM) for a standard
curve (See Note 15).
g. Start the assay.

Fig 5-2. Assessment of NADH and ΔΨm.

Fig 5-3. Spectral scan to detect NADH signal
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Notes
1. The assay can also be done in plate readers without spectral scanning capabilities,
temperature and CO2 control. In that case, it is likely that absolute values will be
different, but the assay will still be useful for comparing experimental conditions.
Data about basal respiration, maximal respiratory capacity and ATP-linked
respiration can be obtained in separate experiments using a classical respiratory
assay with sequential addition of oligomycin, CCCP, and rotenone + antimycin A.
2. It is critical to include BSA in the MAS buffer to preserve mitochondrial coupling
[258]. Rock BSA-containing tubes gently. Avoid vortexing in case of bubbles.
3. Prepare MAS-BP 5-10 min before Seahorse sensor calibration is complete.
Minimize the time cells are in MAS-B. MAS based media are not balanced for
ionic strength.
4. Store RM buffer stocks parts 1 and 2 separated, since Ca2+ may precipitate during
storage. Prepare an aliquot of the working solution the day of the assay.
5. The demands for substrates such as insulin, may differ between cell types.
Consider titrating PMP, and measuring cytochrome-C release by western blot for
cell lines that may be sensitive to permeabilization. In our hands, 3 nM PMP does
not permeabilize mitochondrial membranes in HepG2 and SNU-449 cancer cells.
6. Determine the optimal cell density empirically by considering inhibitor/ substrate
responses for each cell type. If cross cell line comparisons are needed, determine
mitochondrial content by quantifying the mitochondria to cell volume fraction, or
the average amount of mitochondria per cell. This will reduce the possibility of
OCR miscalculations caused by differences in mitochondrial content.
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7. Be careful to aspirate media with a multichannel pipette instead of a vacuum
aspirator to prevent cell detachment. All media should be removed by placing the
pipette tip against the side of the well without touching the bottom. As described
in Note 3, minimize the time cells are in MS-B and the transition to MS-BP.
8. The Mix - Measure cycles can be adjusted. However, the minimum time required
to obtain consistent rates is typically 2 min. To reduce the probability of cells
detaching during the assay (variable for some cell lines), keep the total length of
the permeabilized cell assay to less than 1.5 h.
9. TMPD is a Complex IV –specific electron donor. It is important to protect TMPD
from light and moisture to avoid oxidation. Make TMPD stock in DMSO before
diluting with 1X MAS-BP containing ascorbate. TMPD needs to be maintained in
solution with ascorbate to keep its reductive capacity and to prevent autoxidation.
An indicator that TMPD has been oxidized is a change from yellow-green to
purple in solution. If possible, prepare fresh working solutions before each assay.
Rotenone and antimycin A are inhibitors for complex I and II, respectively.
Succinic acid is substrate for complex II and ascorbate and TMPD for complex
IV. The final concentration of all compounds in the wells will be diluted to 1X of
the port concentrations described in Methods. The higher OCR compared to
baseline in the presence of ASC+TMPD can be explained by the low proton
motive force (pmf) at complex IV of the ETC. Generally, the lower the pmf the
easier it is for electrons to pass along the ETC and reduce O2 to water [259].
10. To avoid inconsistencies with protein measurements, take into account the BSA
content in the MAS-BP media. The permeabilized cell protocol is not compatible
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with most imaging methods to estimate cell number because cells will be prone to
detaching soon after the assay is complete. This is not a concern for the intact cell
protocol. Vibrant Green and Hoescht can be used to label nuclei in live cells.
11. Protect Succinate-NV (a cell permeant succinate analog) from light and store
stocks at -20 °C for up to 3 weeks. Succinic acid is not cell permeant. Both
Succinate –NV and Succinic acid are complex II substrates. It is advisable to
titrate Succinate-NV for each cell type since high concentrations (typically above
1 mM) inhibit mitochondrial respiration. High Succinate-NV releases
formaldehyde which inhibits glycolysis. This factor should be considered if
lactate or extracellular acidification rates will be determined in parallel.
12. Incubation of cells with TMRM in the low nm range, non-quench mode, typically
10- 50 nm, allows a linear association of changes in fluorescence intensity with
ΔΨm calculated using the Nernst equation. It is critical to assess the quench limit
for each cell type. Intramitochondrial accumulation of TMRM is influenced also
by differences in plasma membrane potential (ΔΨp). Ideally, a plasma membrane
potentiometric probe should be co-loaded with TMRM to determine ΔΨp
contribution to changes in TMRM accumulation in mitochondria. Addition of the
multidrug resistance pump, zosuquidar, prevents TMRM efflux.
13. Fluorophores similar to TMRM can undergo a slight spectral shift when diluted in
certain media. An ~3 sec spectral scan on a standard microplate reader allows the
identification of optimum excitation/emission wavelengths.
14. To reduce the amount of TMRM attached to the walls of culture plates, and to
preserve cell attachment, replace half of the initial volume of PM with fresh PM.
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If plate reader is equipped with temperature and CO2 regulation, wait 15 min after
the culture plate is inside the reader to avoid temperature fluctuations that may
affect TMRM equilibration. If local plate reader is not equipped with CO2
regulation, exclude sodium bicarbonate from PM.
15. β-NADH fluorescence will respond linearly to the excitation as concentration
increases. Culture plates need to be UV-transparent, allowing detection at 340 nm.
16. Determination of TMRM and NADH fluorescence can be confirmed by widefield
or confocal microscopy as shown in (Fig. 5-2.)
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Chapter 6 : Targeting the NADH-binding pocket
on VDAC to Modulate Mitochondrial Metabolism
Introduction
Cancer bioenergetics and cancer metabolism are contributed both by aerobic
glycolysis and oxidative phosphorylation (oxphos). In the early 20th century, Warburg
showed that at physiological partial pressures of oxygen, tumors produce more lactic acid
than non-tumor tissues [19]. Warburg even proposed that damaged mitochondria were the
origin of cancer, a theory proved wrong shortly after. In fact, both high glycolysis and
oxidative metabolism contribute to tumor cell metabolism in different proportions [22,
24-27]. The current consensus is that the Warburg phenotype favors proliferation by
providing carbon backbones and metabolic intermediaries needed for the synthesis of
biomass [124, 260, 261]. The relative contribution of mitochondria to generation of ATP
and metabolic intermediaries, varies among tumor types, within the same tumor, and
during tumor growth, indicating a spatiotemporal dynamic regulation of oxidative
metabolism. The interdependency between enhanced glycolysis and mitochondrial
metabolism, is a key feature contributing to the metabolic heterogeneity, increasingly
recognized as a cause of failure in chemotherapy. Thus, mitochondria appear as an
attractive target to develop novel “metabolic” treatments to inhibit cell proliferation [45,
262, 263].
Maintenance of mitochondrial metabolism depends on an adequate influx of
respiratory substrates, cytosolic ATP, ADP, Pi and small ions into mitochondria; and the
efflux of ATP and metabolic intermediaries to the cytosol. To reach the mitochondrial
matrix, most anionic metabolites and small ions cross the outer mitochondrial membrane
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(OMM) through Voltage dependent anion channels (VDAC). VDAC (~30 kDa), is the
most abundant protein in the outer mitochondrial membrane, comprising three isoforms.
In most mammalian cells, VDAC1 and 2 are the most abundant, whereas VDAC3 is the
least expressed isoform; except for testis and spermatozoa [60, 61]. NMR and X-ray
crystallography have shown that VDAC1 and 2, form a transmembrane β-barrel protein,
with 19 anti-parallel β-strands and an N-terminal α-helical region located within the pore
[176, 264]. VDAC inserted in non-polarized or weakly polarized membranes (close to 0
mV), stays mostly in the high conductance open state. By contrast, applied positive or
negative membrane potentials induce conformational changes to several lower
conductance, closed states (maximal at -45 mV or +45 mV) [79, 159]. Although gating
and selectivity for VDAC1 and VDAC2 are very similar in different cell types, the
detailed molecular determinants of voltage gating are still incompletely understood.
Regardless of the mechanism controlling gating, the flux of polar metabolites
through VDAC is determined mostly by their charge and size [90, 91]. VDAC is
selective for anionic metabolites and small cations [70, 83, 84]. The open state of VDAC
allows the flux of anions including most respiratory substrates as mentioned before. In
the closed states, VDAC favors a non-selective flux of small cations [55, 81].
Consequently, physiological or pharmacological regulations that induce a change from
the open state to the closed states of VDAC, decrease and increase the flux of negatively
charged metabolic substrates and cations, respectively. Even though VDAC was initially
considered to be constitutively an “all-time open gateway,” allowing the unrestricted flux
of metabolites, subsequent research showed multiple endogenous regulations. NADH,
α/β tubulin heterodimers, hexokinase, alpha-synuclein, p53, bcl2 family members and
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mitochondrial creatine kinase among others regulate VDAC opening [87, 92, 94-96].
Post-translational modifications, mainly phosphorylation by protein kinases, GSK3β,
PKA, and protein kinase C epsilon (PKCε), inhibit association of VDAC with other
proteins and also regulates VDAC opening [100, 265].
Overall, the movement of metabolites through VDAC depends on the
concentration gradient across the OMM, the electric field, the number of channels, the
selectivity-permeability to a particular metabolite, and the open probability of the
channel. Thus, VDAC emerges as a potential pharmacological target to modulate
mitochondrial metabolism in cancer cells. However, major limitations to develop VDACtargeting drugs have been the isoform specificity, the lack of an identified druggable
region, and a poor understanding of mechanisms regulating gating of the channel.
Moreover, the mechanisms of action of several compounds, claimed to bind to VDAC,
remain unknown. Recently, an NADH-binding pocket in VDAC1, with an amino acid
sequence conserved in all VDAC isoforms, has been identified [176]. The β-NADH
binding to the pocket reduces VDAC conductance by steric occlusion of the pore without
changes at the α-helix, suggesting that molecules binding to this site may prevent VDAC
closing by endogenous regulators.
Here, we hypothesize that small molecules targeting the NADH-binding pocket of
VDAC will block the binding of NADH and possibly other endogenous regulators to the
site, maintaining the channel in an open configuration. Using an in silico approach
followed by biological assays, we identified the lead compound SC18. Short-term
treatment with SC18, decreased mitochondrial membrane potential (ΔΨm), NADH and
ATP, and increased basal respiration. Long-term exposure to SC18 decreased cell
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proliferation and promoted cell death in a dose-dependent fashion. Our result suggests
that decreased cell proliferation and cell death induced by SC18 is mediated by
mitochondrial dysfunction.

Results
Identification of VDAC inhibitor SC18
We screened in silico the South Carolina Compound Collection SC3, using a
shape-based query, as described in Material & Methods. We chose the nicotinamide
moiety, that interacts directly with the NADH binding pocket, and the sugar ring attached
to a phosphate molecule, omitting the adenine group that sterically occludes the VDAC1
pore (Fig 6-1.). The in silico screen yielded 72 compounds with the lowest scoring
docking energies. The 72 compounds were further tested for their ability to induce
changes in TMRM fluorescence, and indicator of ΔΨm, used as a readout of overall
mitochondrial metabolism. We established an arbitrary threshold of 40% change in
TMRM fluorescence compared to baseline, as a criterion to select hits. We identified
SC18 as our most potent hit using this screening strategy.
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Figure 6-1. Drug screening strategy.
In silico screening of the South Carolina Compound Collection SC3 was used
for a shape-based query for compounds structurally similar to NADH, or to
the docking surface of the NADH binding pocket on VDAC. In silico
selected compounds were used in a cell based, phenotypic screening, to
identify compounds based on the capability of causing a minimum of 40%
change in ΔΨm. After identification of SC18, as the most potent compound,
other bioenergetics parameters were evaluated.
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SC18 binds to VDAC
To predict a potential binding mode to the target, we used both an in silico and a
wet-lab approach. We overlaid the SC18 docking pose and β-NADH, in the NADH
binding pocket of VDAC1 (NMR structure, 6TIR). The predicted binding pose of SC18
indicates that it may bind to the NADH-binding pocket in a very similar orientation
compared to β-NADH.
To determine if SC18 bound to VDAC, we incubated SC18 with recombinant
VDAC 1 purified from E. Coli (43), and performed an isothermal calorimetric assay with
β-NADH as positive control, using a NanoTemper Tycho NT. 6 instrument. SC18
addition to VDAC1, similar to β-NADH, caused a temperature shift of ~7 °C indicating
that SC18 binds to VDAC1 (Fig. 6- 2B).
For clarity on the binding of SC18, a transparent surface is shown for NADH
bound to the NMR structure of VDAC (Fig. 6-2 C). The quinazolinedione scaffold forms
two hydrogen bonds with lysine 20, one with the backbone and the terminal nitrogen; and
other similar interactions to the ring oxygen from the sugar ring closest to the 1, 4
dihydronicotinamide moiety of NADH. The two pi-cation interactions were found
between the quinazoline-dione and Arginine 218. The 6-nitro substitution formed a
hydrogen bond with Tyrosine 22, similar to the phosphate backbone of NADH. Finally,
the trifluoromethyl overlays with an amide moiety of the 1,4-dihydronicotinamide of
NADH in the binding pocket.

103

Figure 6-2. SC-18 binds to VDAC.
A) Structure of SC18 B) SC18 decreased the inflection temperature at which the protein unfolds,
similar to NADH binding. C) Docking of SC18 overlaid with the native docking site of NADH of
VDAC1, revealed pose depicting points of interaction similar to NADH. Note the quinazolinedione scaffold that forms two hydrogen bonds with Lys20, one with the backbone and with the
terminal nitrogen, the other being a similar interaction to the ring oxygen from the sugar ring
closest to the 1, 4-dihydronicotinamide moiety of NADH. Two pi-cation interactions were found
between the quinazoline-dione and Arg218. The 6-nitro substitution formed a hydrogen bond with
Tyr22 similar to the phosphate backbone of NADH. Finally, the trifluoromethyl overlaid with the
amide moiety of the 1, 4-dihydronicotinamide of NADH in the binding pocket.
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SC18 modulates mitochondrial metabolism
Mitochondrial membrane potential. To initially assess the effects of SC18 on
mitochondrial metabolism, we quantitatively assessed ΔΨm and determined the EC50.
ΔΨm is an overall indicator of mitochondrial metabolism. We loaded HepG2 and
SNU449 cells with the fluorophore potential indicator TMRM, and imaged TMRM
fluorescence by confocal microscopy. Treatment with SC18 for 2 h, decreased ΔΨm by ~
50% compared to vehicle. To determine if the drop in ΔΨm caused by SC18 was
differentially affected by a specific VDAC isoform, we used SC18 at the same
concentration in wild type HepG2, and in VDAC1/2, VDAC1/3 and VDAC2/3 double
KO cells. SC18 (25 µM) decreased similarly ΔΨm in Wt, VDAC 1/2, 2/3, and 1/3 double
KO cells (~ 52%, 46%, 61%, and 44 % respectively) indicating that SC18 was targeting
all VDAC isoforms (Fig. 3A and B.). EC50 (25µM) (Fig. 6-3 C), was calculated based on
changes in ΔΨm, as described in Material & Methods.
NADH generation. Mitochondrial NADH is an indicator of the balance between
oxidation of respiratory substrates in the Krebs cycle that reduce NAD+ to NADH, and
the utilization by the respiratory chain. To assess whether SC18 influenced mitochondrial
NADH generation, we assessed NADH autofluorescence by multiphoton fluorescence
microscopy. SC18 for 2 h decreased mitochondrial NADH by ̴ 15% in HepG2 cells (Fig.
6-4 A-B).
Respiration. Since changes in ΔΨm may or may not be associated with
differences in oxidative phosphorylation, we determined cellular respiration (Oxygen
consumption rates) in SNU449 cells, using a Seahorse XFe96 extracellular flux analyzer.
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Cells were incubated in the presence of 1, 3, 10, or 30 µM SC18 for 2 h. SC18
increased basal respiration in a dose-dependent fashion ( ̴ 154 pmol/ min/ 3.5 X
104 cells) to a maximum of ̴ 243 pmol/ min/ 3.5 X 10 4 cells at 30 µM) (Fig.6-4
C).
ATP production. To determine if SC18 also influenced ATP production,
we measured cellular ATP using a luminescence assay. SC18 (30 µM) for 2 h,
decreased ATP by ̴ 24%; indicating that the increase in respiration was not
coupled to a higher synthesis of ATP (Fig. 6-4 D).
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Figure 6-3. SC18 decreases mitochondrial membrane potential.
HepG2 cells treated with SC18 (25 µM) for 2 h were loaded with TMRM, as described in
Materials and Methods. A) SC18 decreased ΔΨm in WT, VDAC 1/2 KO, 2/3 KO, and 1/3
KO cells. Representative images pseudocoloured according to the reference bar. B)
Quantification of TMRM relative fluorescence after SC18; C) The half maximal effective
concentration of SC18 (EC50) was determined using TMRM fluorescence as a readout. *
p<0.05 from 3 independent experiments. 4-5 randomly selected fields with 10-20 cells/field
were analyzed. a.u.: arbitrary units.
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Figure 6-4. Short-term treatment with SC18 modulates cellular bioenergetics.
Cells were treated with SC18 for 2 h. A) SC18 decreased mitochondrial NADH, assessed by
multiphoton confocal microscopy, as described in Materials and Methods. NADH
autofluorescence were converted to gray scale; B) Quantitative analysis of NADH
autofluorescence; C) Basal respiration after SC-18 was determined using a Seahorse XFe96
Analyzer, as described in Material & Methods. D) Cellular ATP was measured using a
luciferase based assay. *p<0.05 from 3 independent experiments. 4-5 randomly selected
fields with 10-20 cells/field were analyzed for NADH autofluorescence. a.u.: arbitrary units
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SC18 is cytotoxic
To determine if long-term exposure to SC18 would inhibit cell proliferation and
eventually cause cell death, we assessed cell viability using a trypan blue exclusion assay.
SC18 decreased SNU-449 cell viability by more than 50% at concentrations higher than
24 µM for 5 d. Based on this method to assess viability, we determined an LC50 of 24
µM for SC18 (Fig. 6-5 A).
SC18 delays wound healing.
To confirm if cell viability was associated also a decrease in cell migration and
proliferation, we used a scratch assay. Images were taken at 8 h intervals up to 48 h (Fig.
5C) after treatment with SC18 (24 µM) (Fig. 6-5 B). Sorafenib, a chemotherapeutic agent
that promote hepatocarcinoma cell death, was used as a positive control. SC18 delayed
wound healing similar to SOR (5 µM). The maximal inhibitory effect ( ̴ 50% inhibition),
occurred 24 h after treatment. 48 h after treatment, the inhibition effect of SC18 on
wound healing was still ̴ 30%.
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Summary

Following our in silico and physical drug screening approaches, we identified
SC18 as a VDAC binder. SC18 is our most potent compound that decreases ΔΨm.
Similar to ΔΨm, NADH and ATP generation decreased in the presence of SC18.
Although decreased ΔΨm, NADH and ATP would be consistent with decreased
mitochondrial metabolism, the increase in respiration induced by the lead compound may
contradict this interpretation. Overall, our findings indicate that SC18 decreases
mitochondrial metabolism.
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Chapter 7 :
Directions

General

Discussion

and

Future

Discussion
Tumor initiation, progression, and metastasis require continuous metabolic and
energetic adaptations, in part, mediated by metabolic reprogramming. The metabolic
plasticity that contributes to tumor heterogeneity, is influenced by the ability to rapidly
adjust the relative contributions of glycolysis and mitochondrial metabolism to the
bioenergetics and biosynthetic demands. The initial finding of Warburg, showing
enhanced aerobic glycolysis as the main metabolic hallmark of cancer, has been
embedded as a dogma for decades. Moreover, the magnitude of glycolysis in a tumor is
still considered by many, an indicator of malignancy. In this context, the relevance of
mitochondrial metabolism in cancer has been underestimated until recently.
The resurgence of cancer metabolism as a relevant research topic in the last 30 years has
been accompanied by growing evidence indicating that mitochondria in cancer are not
mere bystanders but active players in cell proliferation.
Although, initially, therapies targeting cancer metabolism were designed to inhibit
glycolysis, a better comprehension about the role of tumor mitochondria unveiled several
novel targets. Currently, both inhibition and increase of mitochondrial metabolism are
being investigated. Pharmacological inhibition of mitochondrial metabolism may slow or
stop cell proliferation by promoting mitochondrial dysfunction and decreasing the
biosynthetic capabilities of mitochondria. By contrast, mitochondrial enhancers increase
mitochondrial metabolism and ROS formation leading to oxidative stress and cell death.
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In addition, in metabolically flexible tumors, increased mitochondrial metabolism
indirectly decrease glycolysis reverting the Warburg metabolism.

Sorafenib and VDAC openers common actions
Investigation into the mechanism of action of new and pre-existing
chemotherapeutics can help to identify new targets as well as improve upon the efficacy
of cancer treatment. VDAC-tubulin antagonists are a potential new class of
chemotherapeutic agents that promote cancer cell death by switching the Warburg
metabolic phenotype to a more oxidative metabolism. This in turn, promotes oxidative
stress [181, 182]. Previously, we have shown that the antagonism of the inhibitory effect
of tubulin on VDAC by erastin, and erastin-like compounds causes mitochondrial
dysfunction. In this work, we show some common mechanism of action for the erastinlike small molecule X1, and the multikinase inhibitor sorafenib, which involves JNK
activation and alterations in mitochondrial bioenergetics.
Sorafenib and X1 activate JNK
Sorafenib and X1 both depolarize mitochondria, but the mechanisms underlying
the drop in ΔΨm, a readout of mitochondrial function, are incompletely understood [201,
203, 266, 267]. It has been reported that sorafenib inhibits ETC complexes I, II, III and
the ATP synthase, while promoting glycolysis [267, 268]. In our hands, sorafenib or X1
both depolarize mitochondria (Fig. 3-1). Among different mechanisms, activation of JNK
assessed by JNK-phosphorylation, is shown to disrupt mitochondrial function [217].
Here, we showed that X1 progressively increased JNK phosphorylation, reaching a
plateau within ~60 min in Huh7 cells. A similar pattern was observed in HepG2 cells
(Fig. 3-3). Activation of JNK either preceded or accompanied mitochondrial
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depolarization. Additionally, JNK inhibitors VIII or SP600125 prevented ΔΨm
depolarization.
Overall, these results show that JNK activation is a necessary step to induce
mitochondrial dysfunction after X1 or sorafenib. Interestingly, JNK inhibition did not
prevent mitochondrial hyperpolarization after X1; this suggests that mitochondria remain
functional during the initial hyperpolarization after X1. A hyperpolarizing phase
preceding mitochondrial depolarization has not been observed after sorafenib.
X1 induces superoxide production at complex III of the ETC
ROS and JNK are reciprocally dependent, and participate in a self-amplifying
positive

feedback

loop

[269].

Previously,

we

showed

that

mitochondrial

hyperpolarization induced by X1 was followed by increased mitochondrial ROS
generation [181]. Similarly, oxidative stress induced by sorafenib is extensively
documented [222, 270]. Here, we showed that both sorafenib and X1 induced robust
increases (> 4 fold) in O2•- production in HepG2 and Huh-7 cells (Fig. 3-6).
O2•-, converted to H2O2 by the superoxide dismutases, is mainly produced in
mitochondria. The outer quinone-binding site in Complex III (site IIIQo) generates O2•distributed about equally to each side of the mitochondrial inner membrane whereas other
sites like the quinone-binding site in complex I (site IQ) generates O2•-/ H2O2 to the
mitochondrial matrix [271, 272]. Thus, a large portion of O2•- generated at site IIIQo is
released to the cytosol where it activates JNK among other effects [273, 274]. While O2•production induced by sorafenib is well established, the site of production of O2•- after X1
has not been determined. To determine major mitochondrial sites of ROS formation after
X1 and sorafenib we used S3QEL2, a compound that specifically inhibits O2•- production
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at site IIIQo. S3QEL2 does not alter oxidative phosphorylation and maintains respiration
without promoting a redistribution of electrons to other ROS generating sites in the
electron transport chain. Thus, S3QEL2 allows a specific assessment of the contribution
of IIIQo to O2•- formation. S3QEL2 prevented mitochondrial depolarization after X1,
indicating that site IIIQo is a major contributor of O2•- to drive cytosolic JNK activation
and subsequent mitochondrial depolarization induced by X1 (Fig. 3-7).
X1 or sorafenib induced activated JNK translocates to mitochondria
Phosphorylation of Sab by JNK blocks electron transport at Complex I or II,
promoting ROS formation and decreasing oxphos [275]. Here, we used the Tat-sabKIM1
peptide to block mitochondrial translocation of activated JNK that is downstream of
ROS-dependent activation of JNK [276, 277]. We showed that Tat-sab

KIM1

peptide

prevented mitochondrial dysfunction induced by X1 and sorafenib, indicating that
mitochondrial dysfunction induced by both compounds requires not only activation of
JNK but also JNK translocation to mitochondria (Fig. 3-8).
Persistent JNK activation is associated with cell death signaling. Sorafenib
induces apoptotic cell death but the mechanism of cell death after VDAC opening had not
been determined [276, 277]. After X1, simultaneous uptake of annexin V and PI occurred
~ 6 h after X1 in 100% of cells indicating necrosis (Fig. 3-9). Necrostatin-1 completely
blocked X1-induced annexin V staining and PI uptake signifying that X1 may induce
necroptosis [278]. Increased ROS formation has been reported also to cause necroptosis
in different cancer cell lines including

HCT116 and HT29 [279, 280]. Here, JNK

inhibition partially prevented cell death after X1, suggesting that mitochondrial
dysfunction promoted by JNK is an important driver of necroptosis (Fig. 3-10).
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Refining our approach to ΔΨm as a readout of mitochondrial function
In these studies, we use the very reliable, ΔΨm as a global readout of
mitochondrial function and observed, just as many others before us ΔΨm heterogeneity.
Until now, this phenomenon was only described qualitatively or at best, semiquantitatively [37,12,18,38]. Using an advanced confocal microscopy approach, we
quantified ΔΨm differences among cells in absolute millivolt (mV) values and proved
that ΔΨm heterogeneity is an intrinsic property of mitochondria.
Despite being a well-known phenomenon, the molecular mechanisms responsible
for the intercellular differences in ΔΨm in physiological and pathophysiological
conditions are poorly understood. Rate of cell proliferation, exposure to nutrients, and
metabolic reprogramming, reported as influencing tumor heterogeneity, may also
contribute to heterogeneity of ΔΨm [7,39,40]. Additionally, lipophilic and cationic
fluorescent probes are widely used tools for qualitative and semi-quantitative
determination of relative changes in ΔΨm based on their Nernstian behavior and their
misuse may also contribute to inaccuracies about ΔΨm heterogeneity [42,43].
Membrane potentials are quantitative in non-quenching mode
In this work, we used both Rh123 and TMRM, because of the strong fluorescent
quantum yields for these dyes, and the sensitivity to detect subtle changes in both ΔΨm
and ΔΨp (Fig. 4-1). Rh123, has been reported to inhibit the ETC, to require extended
incubation times to reach equilibrium of distribution, and to be a substrate for multidrug
resistant pumps (MDR) on the cell surface [23,31]. To rule out potential artifacts
associated with the use of Rh123, we used non-quenching concentrations and sufficient
incubation times as confirmed by a steady baseline after 90 min in the presence of
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zosuquidar, an MDR pump inhibitor. Inhibition of MDR pumps partially reduced ΔΨm
heterogeneity; indicating that differential MDR activity among these cells is only a minor
contributor to intercellular differences in ΔΨm. Another factor potentially influencing
TMRM fluorescence is the use of the dye in quench or non-quench mode. The low ΔΨp
in hepatocytes-derived cancer cell lines predictably raised the quench limit of probes
including TMRM above the often reported ~20 nM [29]. Here, we confirmed that we
used TMRM and Rh123 in non-quench mode by adding the uncoupler CCCP, that did
not cause the transient increase in whole cell fluorescence observed when TMRM is in
quench mode. The use of TMRM in non-quench mode allowed quantitative and semiquantitative assessment of native ΔΨm heterogeneity among cells and linear associations
during treatments, as well as limited the possibility of direct inhibition of the ETC by
these dyes.
Heterogeneity of ΔΨm and ΔΨp do not correlate intercellularly
In our study, the concurrent analysis of the ΔΨp indicator DiBAC4(3) and
TMRM fluorescence, did not show correlation (Fig. 4-2). One possible explanation is the
limitation of the binding kinetics and affinities of the dye not linked to actual variances in
ΔΨp. DiBAC4(3) binds to intracellular proteins and hydrophobic binding sites,
increasing the fluorescence of the probe [45]. Furthermore, it is reasonable to expect no
correlation between the two variables if differences in ΔΨp among cells are not very high
compared to differences in Ψm, or if the binding of the dye to subcellular structures is
variable, as indicated by bright subcellular aggregates (Fig. 4-2 A). This initial
interpretation about the lack of correlation between ΔΨm and ΔΨp was further confirmed
by using the absolute calibrated TMRM/FLIPR assay. This method cancels geometric
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and binding effects using an internal calibration and it also includes the P-glycoprotein
MDR pump inhibitor, zosuquidar. A partial correlation between ΔΨm and ΔΨp was
observed using this approach (Fig 4-3 C). The majority of cells in a cancer cell line
showed similarly low ΔΨp (~20 mV) indicating that the magnitude of ΔΨm
heterogeneity was not driven by intercellular differences in ΔΨp (Fig. 4-3 C).
Possible sources of ΔΨm heterogeneity
Mitochondrial membrane potential formation depends on a complex sequence of
intra-mitochondrial biochemical reactions, associated to the oxidation of respiratory
substrates in the Krebs cycle. NADH, a major by-product of the Krebs cycle, enter the
ETC as an electron donor. The flow of electrons in the ETC creates and electrochemical
gradient used for ATP synthesis. Thus, ΔΨm is an indicator of overall mitochondrial
function and mitochondrial metabolism, influenced, among other factors, by the supply of
substrates and the demand for ATP. The ATP demand depends indirectly on cellular ATP
consumption and the proton leak through the mitochondrial inner membrane that makes
mitochondrial ATP production less efficient. In cancer cells, aerobic glycolysis, a
mitochondrial-independent supplier of ATP in the Warburg phenotype, partially cope
with the cellular demand for ATP, decreasing the metabolic pressure on mitochondria.
Therefore, possible sources of ΔΨm heterogeneity include variable mitochondrial
substrate oxidation and proton leak, relative contribution of glycolysis, and total ATP
demand. An interesting observation of our study is that the magnitude of ΔΨm
heterogeneity differ between cell lines raising questions about the biological meaning of
the differences [13]. Theoretically, the higher the ΔΨm, the higher the energy capacity of
the inner mitochondrial membrane to generate ATP. Although previous reports in
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different cancer models showed higher ΔΨm in cancer cells compared to non-tumors
counterparts, the differences in ΔΨm has been only assessed in terms of relative
fluorescence and experimental bias related to ΔΨp, geometry, binding, kinetic factors
may have been underestimated [46,47].
Membrane potential heterogeneity is intrinsic to mitochondria
A possible role for the balance between demand and supply on the maintenance of
ΔΨm can be inferred by using specific inhibitors of respiratory complexes or the ATP
synthase. ATP synthase inhibition by OLIGO reduced the heterogeneity by inducing a
more robust hyperpolarization in low ΔΨm compared to high ΔΨm cells. It is likely that
a differential response to OLIGO between cell populations be caused by a higher ATP
demand, lower glycolysis and lower mitochondrial supply of respiratory substrates in
basa low ΔΨm cells. Because of the specificity of OLIGO to inhibit the ATP synthase, no
modification in the proton leak could cause the differential response (Fig. 4-5). To further
study possible mechanisms explaining ΔΨm heterogeneity, we inhibited the respiratory
chain with antimycin A. Antimycin A depolarized ΔΨm more intensely in high ΔΨm
cells and decreased overall ΔΨm heterogeneity (Fig. 4-6). Importantly, in the presence of
antimycin A, ΔΨm was maintained at a lower level by the hydrolysis of glycolytic ATP.
Overall, the experiments with OLIGO and antimycin A suggest that heterogeneity of
ΔΨm was contributed mostly by intra-mitochondrial regulatory mechanisms.
Cell cycle influence on ΔΨm heterogeneity is minimal
The cell cycle, by imposing different metabolic demands, could also be another
cause of ΔΨm heterogeneity. Since cancer cells in culture are unsynchronized, and cells
during G1, S, G2 and mitosis have different metabolic needs, we hypothesized that ΔΨm

119
heterogeneity was dependent on the phase of the cell cycle. Synchronization of cells in
G1, S and G2 allowed us to investigate ΔΨm heterogeneity in each subpopulation of cells
(Fig. 4-4). Interestingly, ΔΨm remained heterogeneous throughout the phases of the cell
cycle with shifts in the ratios of high, intermediate and low ΔΨm cells. In particular, we
observed a gradual increase of ΔΨm from G1 to G2 phase. Information regarding the
coordination of mitochondrial bioenergetics and cellular proliferation is still scarce.
However, a recent report showing a concurrent increase of ΔΨm, mtDNA and
mitochondrial mass from early G1 to G2, partially supports our findings [48]. The current
understanding of the relationship between energy supply and the cell cycle progression
points to a bidirectional interplay [49,35,50]. In line with this finding, it has been shown
that depolarization of mitochondria triggered a specific G1–S arrest, demonstrating that
mitochondrial function is important for G1-to-S transition [51]. The underlying
mechanisms are unknown and certainly will drive future investigations, for example, to
simultaneously assess ΔΨm and other parameters of mitochondrial function including
ATP and NADH production during cell cycle progression.
Building on our knowledge of ΔΨm, a quick method to assess mitochondria
To expand our finely tuned understanding of ΔΨm as a readout of mitochondrial
health and functionality, we developed a novel, sensitive and fast method to assess ΔΨm,
NADH generation and electron flow in permeabilized and intact cells using a
combination of plate reader and respirometry assays. This method provides fast-tracked,
medium throughput outcomes in phenotypic assays of mitochondria with an aim to scale
up drug screening efforts.
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NADH, respiration, and ΔΨm give a snapshot of mitochondrial function
Respiratory substrates are catabolized in the Krebs cycle to generate NADH that
donates electrons entering the ETC at complex I, to initiate oxidative phosphorylation.
The subsequent flow of electrons through complexes II, III and IV to the final acceptor
O2, promotes pumping of protons to the IMS at complexes I, III, and IV, to generate a
negative ΔΨm in the matrix. In the coupled respiration, protons from the IMS are used by
ATP synthase to generate ATP. Thus, NADH generation, respiration, and ΔΨm, are
dynamic readouts of mitochondrial metabolism that accurately reflect mitochondrial
bioenergetics [251]. With a plate reader, equipped with an environmental chamber and
temperature control, NADH and ΔΨm can be assessed to complement respirometry in
minutes.
Study the activity of individual proteins in the ETC
Thorough assessment of mitochondrial function is multidimensional, time
consuming, and usually requires expensive equipment and specific training. The novelty
of this method is it aids the study of the activity of individual proteins in the ETC in live
cells. This is possible because of the recent development of succinate-NV, a cell
permeant analog of succinate; allowing assessment of complex II of the ETC. Previously,
this type of assessment was limited to isolated mitochondria or permeabilized cells.
Although the permeabilized cell approach provided the option to assess mitochondria in a
more physiologically relevant environment, the inner mitochondrial membrane was
highly compromised because of harsh detergents such as digitonin or saponin, often
leading to the release of cytochrome c. Our method improves upon this, not only with the
intact cell approach, but also in our permeabilized cell system. Our use of the plasma
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membrane permeabilizer, which makes tiny holes limited to just the plasma membrane of
cells, sparing mitochondrial membranes, distinguishes our method very well. Once
adapted to a specific cell type, this method can be used to screen drug libraries for
mitochondrial targets, limiting the possibility of false positives.
Advancing to a more refined drug discovery approach to targeting VDAC gating
Regardless of the extensive research on VDAC structure and function in
reconstituted systems, many questions about VDAC regulation and function in
physiological and pathological conditions remain undetermined. A potential redundancy
in function, and different metabolic roles for each isoform, proposed as likely happening
in the intracellular milieu, has not been supported by experimental data. From a
pharmacological perspective, the success of modulating VDAC opening is, most likely to
occur if the three isoforms are targeted simultaneously.
Overall, VDAC opened or closed states are major determinants of mitochondrial
metabolism. However, VDAC isoform specificity and lack of identifiable druggable
regions, have been obstacles to developing drugs that regulate VDAC opening [87].
The VDAC-NADH binding pocket as a target for drug development
Recently, it has been shown that binding of NADH to a specific pocket in
VDAC1 induces closure of the channel [176]. We analyzed the sequence of residues in
the VDAC-NADH binding pocket and found that it is fully conserved in VDAC 2 and 3.
Thus, we hypothesized that the NADH-binding pocket was an excellent pharmacological
target to identify small molecules to occupy the site, prevent the binding of endogenous
regulators, and maintain all VDAC isoforms open. Because of the stereochemical
characteristics of the pocket, we used the nicotinamide moiety and adjacent phosphate
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groups to generate shape-based queries to screen in silico the South Carolina Compound
Collection SC3. After subsequent modeling including molecular docking of initial
candidates, we identified SC18 as a hit compound. We also proved that SC18 binds to
VDAC1. The thermal shift assay that we used indicates if the compound binds or not to
the protein but has the limitation of not identifying specifically an intramolecular binding
site. A precise determination of SC18 binding to the NADH-binding pocket would
require soaking VDAC 1 crystals in the presence of the compound followed by NMR to
identify the binding. Although it is a very interesting prospective, because of the
methodological difficulties involved, this approach is out of the scope of our current
work.
SC18 modulates mitochondrial metabolism
Our in silico strategy was followed by biological assays to identify the most
potent hit. Initially, we used ΔΨm as the readout because it is a global indicator of
mitochondrial function. Maintenance of ΔΨm depends on an adequate flux of metabolites
through VDAC, but also on the activity of the Krebs cycle and a coupled oxidative
phosphorylation. However, ΔΨm is subjected to multiple levels of regulation and
increases or decreases in ΔΨ do not necessarily imply a change in VDAC opening or
closing states. Because of this caveat and to use a multidimensional approach, we studied
other indicators of mitochondrial function.
After identifying SC18 as the most potent compound decreasing ΔΨm, we studied
mitochondrial NADH generation, ATP production and respiration. Similar to ΔΨm,
NADH and ATP generation decreased in the presence of SC18. Although decreased
ΔΨm, NADH and ATP would be consistent with decreased mitochondrial metabolism,
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the increase in respiration induced by the lead compound, seems to contradict this
interpretation. It is possible that SC18 exerts a time dependent biphasic effect. If,
according to our hypothesis SC18 blocks the access of endogenous regulators to the
NADH-binding pocket, it would be reasonable to expect a transient increase in
mitochondrial metabolism followed by mitochondrial dysfunction. Thus, decreased
ΔΨm, ATP, and NADH would reflect mitochondrial dysfunction. The increase in
respiration induced by SC18 is intriguing. Plausible explanations could be a direct, mild
uncoupling effect, independent of VDAC opening, or a down-regulation of pyruvate
dehydrogenase kinase that will leave more pyruvate available for oxidation, among other
mechanisms. In any case, more time-course studies will be necessary to add mechanistic
explanations to the effects of SC18. Overall, our findings indicate that SC18 decreases
mitochondrial metabolism.
SC18 decreases cell proliferation
Mitochondria can contribute up to 90% of total cellular ATP in cancer cells, and
is an essential source of metabolic intermediaries for the synthesis of biomass. Thus,
changes in mitochondrial metabolism may impact not only cellular metabolism but also
cell proliferation. In that sense, we evaluated if the decrease in mitochondrial function
was followed by a decrease in cell proliferation. We showed that long-term treatment
with SC18 (3-5 d), delays wound healing. Since wound healing assays assess not only
proliferation but migration as well, we confirmed the inhibitory effect of SC18 on cell
proliferation by quantifying cell viability and proliferation using trypan blue exclusion
and direct counting. Our results clearly indicated an inhibitory effect of SC18 on cell
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proliferation starting at 10 µM. However, cell death was only observed ( ̴ 96%) at a
maximal concentrations (30 µM).
Future experimentation will be required to determine if SC18 regulates the
conductance of VDAC inserted into lipid bilayers. In addition, the drug discovery process
will continue to generate analogues of SC18 to increase the potency and, possibly, the
specificity. In summary, our findings show that SC18 modulates mitochondrial
metabolism in cancer cells, inhibit cell proliferation and induce cell death.
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Significance and conclusion
This dissertation work sought to add to the body of knowledge in the
relatively new and rapidly evolving field of VDAC gating and its role in mitochondrial
bioenergetics in the context of cancer. This work builds on our model of VDAC opening
leading to a release of the brake on oxphos in cancer cells that otherwise display a
Warburg metabolism; leading to oxidative stress, mitochondrial dysfunction and
eventually cancer cell death. The body of work progresses from the aforementioned
model into a more refined and critical assessment of methods used to assess
mitochondrial biology and the contribution of ΔΨm heterogeneity to cancer
bioenergetics. This informed our development of methods to assess mitochondrial
function in a quick and robust, multidimensional approach. Ofcourse, the timing of the
discovery of the NADH binding pocket by Sebastian Hiller’s group was serendipitous for
our studies and allowed a novel drug discovery approach to pharmacologically target a
specific region of the channel directly. Thus, the lead compound coming from our drug
discovery approach, SC18, may become the first of a series of specific VDAC-targeted
modulators of mitochondrial metabolism, bringing new insights into the channel’s
regulation and relevance to cancer metabolism and tumor progression.
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